Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Clinical Guidelines |16 December 2003

Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography

Robert L. McNamara, MD, MHS; Leonardo J. Tamariz, MD, MPH; Jodi B. Segal, MD, MPH; Eric B. Bass, MD, MPH

Robert L. McNamara, MD, MHS
From Yale University School of Medicine, New Haven, Connecticut, and Johns Hopkins University, Baltimore, Maryland.

Leonardo J. Tamariz, MD, MPH
From Yale University School of Medicine, New Haven, Connecticut, and Johns Hopkins University, Baltimore, Maryland.

Jodi B. Segal, MD, MPH
From Yale University School of Medicine, New Haven, Connecticut, and Johns Hopkins University, Baltimore, Maryland.

Eric B. Bass, MD, MPH
From Yale University School of Medicine, New Haven, Connecticut, and Johns Hopkins University, Baltimore, Maryland.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From Yale University School of Medicine, New Haven, Connecticut, and Johns Hopkins University, Baltimore, Maryland.

    Disclaimer: The authors are responsible for the content of this article, including any treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

    Acknowledgments: The authors thank Karen Robinson and Drs. Marlene Miller, Steve Goodman, and Neil Powe for their valuable contribution to the Evidence-based Report on the Management of Atrial Fibrillation.

    Grant Support: Portions of this background paper were drawn from a review conducted by the Johns Hopkins Evidence-based Practice Center through Contract No. 290-97-0006 from the Agency for Healthcare Research and Quality, Rockville, MD. Dr. Tamariz was supported by a training grant in behavioral research in heart and vascular diseases from the National Heart, Lung, and Blood Institute (T32HL07180).

    Potential Financial Conflicts of Interest:Consultancies: R.L. McNamara (Aventis, EU3); Grants received: L.J. Tamariz (National Heart, Lung, and Blood Institute).

    Requests for Single Reprints: Robert L. McNamara, MD, MHS, Cardiovascular Section, Yale University, 333 Cedar Street, 316 FMP, P.O. Box 208017, New Haven, CT 06520-8017; e-mail, robert.mcnamara@yale.edu.

    Current Author Addresses: Dr. McNamara: Cardiovascular Section, Yale University, 333 Cedar Street, 315A FMP, P.O. Box 208017, New Haven, CT 06520-8017.

    Dr. Tamariz: 2024 East Monument Street, Room 2-516, Baltimore, MD 21205.

    Dr. Segal: 720 Rutland Avenue, Ross #1025, Baltimore, MD 21205.

    Dr. Bass: 1830 East Monument Street, Room 8068, Baltimore, MD 21287.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Methods
    • Data Synthesis
    • Conclusion
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

Abstract

Purpose:

This review summarizes the available evidence regarding the efficacy of medications used for ventricular rate control, stroke prevention, acute conversion, and maintenance of sinus rhythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patients with atrial fibrillation.

Data Sources:

The Cochrane Collaboration's database of controlled clinical trials and MEDLINE.

Study Selection:

Primarily randomized, controlled trials of medications.

Data Extraction:

Paired reviewers obtained data on efficacy and safety. Strength of evidence was assessed.

Data Synthesis:

Recent clinical trial results showed that most patients with atrial fibrillation have similar outcomes with strategies for controlling ventricular rate compared with strategies for restoring sinus rhythm. For efficacy of primary stroke prevention, compared with placebo, evidence was strong for warfarin and suggestive for aspirin. The evidence for an increased risk for major bleeding was suggestive for warfarin and inconclusive for aspirin. For ventricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to digoxin and placebo, particularly during exercise. For efficacy of acute conversion, compared with placebo, evidence was strong for ibutilide, flecainide, dofetilide, propafenone, amiodarone, and quinidine. For efficacy of maintenance of sinus rhythm after conversion from atrial fibrillation, evidence was strong for amiodarone, propafenone, disopyramide, and sotalol. Echocardiography was found to be useful in estimating risk for thromboembolism and potentially useful in estimating likelihood of successful cardioversion and maintenance.

Conclusions:

For several key questions in the pharmacologic management of atrial fibrillation, strong evidence exists to support 1 or more treatment options.

Atrial fibrillation is the most common type of arrhythmia in adults, accounting for about one third of hospitalizations for arrhythmia (1). The prevalence increases from less than 1% in persons younger than 60 years of age to more than 8% in those older than 80 years of age (2-6). The incidence ranges from 0.2% per year for men 30 to 39 years of age to 2.3% per year in men 80 to 89 years of age (7, 8). The age-adjusted incidence for women is about half that of men (9).
The cardiac conditions most commonly associated with atrial fibrillation are rheumatic mitral valve disease, coronary artery disease, congestive heart failure, and hypertension (8, 10). Noncardiac causes include hyperthyroidism, hypoxic conditions, surgery, and alcohol intoxication. A predisposing condition exists in more than 90% of cases (5, 11, 12); the remaining cases have what is called lone atrial fibrillation. Patients with atrial fibrillation frequently have symptoms of hemodynamic compromise, ranging from irregular palpitations to the more insidious feeling of malaise. They also have an increased risk for thromboembolism. Comparing with age-matched controls, the relative risk for stroke is increased 2- to 7-fold in patients with nonrheumatic atrial fibrillation (3, 8, 13), and the absolute risk for stroke is between 1% and 5% per year, depending on clinical characteristics (3, 12, 14-16).
Quality of life is an important consideration for patients. Paroxysmal atrial fibrillation disrupts the lives of patients (17), but this perception may not be associated with frequency or duration of symptoms. Warfarin therapy affects quality of life because of frequent blood testing and recommendations for limiting some activities. Gage and colleagues (18) found that atrial fibrillation decreases utility, a quantitative assessment of quality of life used in decision analysis, by 1.3%. Protheroe and associates (19) found that only 61% of patients would prefer anticoagulation to no treatment, considerably fewer than those for whom guidelines would recommend treatment. Little is known about the direct effects of antiarrhythmic therapy and rate-control therapy on quality of life.
The American College of Cardiology/American Heart Association/European Society of Cardiology Task Force on Clinical Guidelines for the Management of Atrial Fibrillation classified atrial fibrillation into 4 types (20): first detected episode, paroxysmal (terminates spontaneously), persistent (electrical or pharmacologic termination necessary), and permanent (resistant to electrical or pharmacologic conversion or accepted by the physician).
The purpose of this review was to summarize the evidence that was available during formulation of the guidelines developed by the American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) for management of adult patients with nonpostoperative atrial fibrillation. The foundation of this background paper was a systematic review of the pharmacologic management of atrial fibrillation that examined the efficacy of medications used for stroke prevention, ventricular rate control, acute conversion, and maintenance of sinus rhythm, as well as the role of echocardiography in guiding pharmacologic therapy (21). For this updated version of the systematic review, we considered observational data, consensus statements, decision analyses, and relevant guidelines. This review focused on the evaluation and pharmacologic management of adult patients with nonpostoperative atrial fibrillation. The rapidly advancing field of nonpharmacologic management of atrial fibrillation is outside the scope of this paper.

Methods

A full description of the methods used in the systematic review can be found in a detailed evidence report (21). A brief description of these methods and additional methods specific to this article are given below.

Literature Identification

Whenever possible, we focused our searches for relevant evidence on the strongest study design: randomized, controlled trials (RCTs). For our previous systematic review, we identified controlled trials in the CENTRAL database produced by the Cochrane Collaboration's international efforts, searched MEDLINE from 1966 to 1998 for citations tagged as randomized, controlled trial or controlled clinical trial, searched the PubMed Related Articles feature, reviewed hand searches submitted to the Baltimore Cochrane Center, scanned the reference lists in relevant publications, and scanned the table of contents of relevant journals. For the current review, we also searched MEDLINE from May 1998 through September 2001 (using the same search terms as in the original review plus terms to identify meta-analyses and decision analyses). For topics without sufficient RCTs, we used observational data, consensus statements, review articles, and decision analyses obtained from our search of MEDLINE from 1966 through September 2001. Although we had to use September 2001 as a cutoff for the systematic searching of the literature in order to generate a report for the ACPAAFP Guideline group, we included selected studies published after September 2001 on the basis of input from the group.

Article Review Process

Studies were eligible for review if they were randomized trials of adult patients that addressed the management of nonpostoperative atrial fibrillation. In the previous systematic review, 521 citations were identified and 179 articles were eligible for detailed review. The updated search yielded 29 additional articles that met our inclusion criteria.

Statistical Analysis

For the quantitative analysis, we stratified the data to obtain an effect measure for each drug. We used Stata, version 7.0 (Stata Corp., College Station, Texas) to calculate the odds ratio (OR) of success of the drug compared with placebo. Respective 95% CIs and P values were also calculated. We used ORs because they provide less heterogeneity of study results than relative risk ratio. Estimates of the relative rates of the outcomes of interest were pooled by using standard methods for combining the OR for the outcomes of conversion to sinus rhythm, maintenance of sinus rhythm, stroke, peripheral embolism, major bleeding, minor bleeding, and death (21). Studies were weighted on the basis of the precision of the estimate within each study. When no heterogeneity was found, meta-analyses used the fixed-effects model (MantelHaenszel method for pooling) (22). When heterogeneity was found, the random-effects model was used (DerSimonian and Laird method of pooling) (23). An OR was considered significantly different from 1 if the P value was less than 0.05. Statistical strength of evidence was categorized as strong (P 0.01), moderate (0.01 < P 0.05), suggestive (0.05 < P 0.2), or inconclusive (P > 0.2).

Role of the Funding Sources

The initial systematic review was funded through a contract with the Agency for Healthcare Research and Quality (21). Subsequent work was supported by the American College of Physicians. Drafts of the manuscript were reviewed by members of the ACP/AAFP guidelines committee for management of atrial fibrillation.

Data Synthesis

Does Aggressive Rhythm Control Improve Mortality and Morbidity Compared with Rate Control?

Although the relative benefits and risks of rate versus rhythm control are of paramount importance in the management of atrial fibrillation, studies directly addressed this issue only recently. By far the largest, the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial was a multicenter RCT that enrolled 4060 patients from more than 200 sites in Canada and the United States (24). Eligibility criteria included documented atrial fibrillation lasting at least 6 hours and at least 1 risk factor for stroke (age >65 years, hypertension, diabetes mellitus, previous stroke, and poor ventricular function). Average age was 70 years. Sixty-one percent of patients were men, 89% were white, 71% had hypertension, 38% had coronary artery disease, and 18% had had failure of antiarrhythmic therapy. After patients were randomly assigned to the rhythm-control or rate-control group, physicians could choose from a list of pharmacologic and nonpharmacologic therapies. Although anticoagulation was continued indefinitely for the rate-control group, discontinuation of anticoagulation was permitted at 1 month or later following conversion in the rhythm-control arm. The mortality rate at 5 years was 23.8% in the rhythm-control group and 21.3% in the rate-control group (hazard ratio, 1.15 [95% CI, 0.99 to 1.34]; P = 0.08). Combined central nervous system ischemic strokes and hemorrhagic events occurred in 8.9% of patients in the rhythm-control group and 7.4% of patients in the rate-control group (P > 0.2). Eighty-five patients in the rhythm-control group and 79 in the rate-control group had strokes (P > 0.2). Of note, more than 70% of the strokes in both groups occurred in patients who had stopped taking anticoagulant therapy or who had an international normalized ratio less than 2.0. Preliminary analyses of other secondary end points, including quality of life and functional capacity, did not show statistical difference between treatment groups. However, more hospitalizations occurred in the rhythm-control group.
A smaller study conducted in the Netherlands, the RAte Control versus Electrical cardioversion for persistent atrial fibrillation (RACE) study (25), randomly assigned 522 patients to aggressive rhythm control or rate control only. Mean age was 68 years. Sixty-four percent were men, 49% had hypertension, and 27% had coronary artery disease. The primary composite end point of cardiovascular mortality, heart failure, thromboembolic complications, bleeding, pacemaker implantation, and severe side effects of antiarrhythmic drugs occurred in 17.2% of patients in the rate-control group and in 22.6% of patients in the rhythm-control group over a mean of 2.3 years. Thus, rate control was not inferior to rhythm control in this group. In subgroup analysis, the potential benefit of the rate-control strategy was seen only in patients with hypertension; fewer primary end points occurred in the rate-control group (17%) than in the rhythm-control group (31%). Rates were similar for those without hypertension (17% and 13%, respectively).
Another small study, the Pharmacological Intervention in Atrial Fibrillation trial (PIAF), recruited 252 patients with new-onset or permanent symptomatic atrial fibrillation (26). One group of 125 patients received rate control with diltiazem. The other group of 127 patients was aggressively converted from atrial fibrillation, many times if necessary, and received amiodarone to maintain sinus rhythm. Although distance achieved on a 6-minute walking test was improved in the rhythm-control group, relief of atrial fibrillationrelated symptoms was similar in both groups. The results indicated that in a patient with atrial fibrillation, controlling ventricular rate could be equivalent to the costly and difficult task of maintaining sinus rhythm.
The pilot study Strategies of Treatment of Atrial Fibrillation (STAF), which has been presented but not yet published, was performed in 11 centers in Germany and included 200 patients with atrial fibrillation. Patients were randomly assigned into 2 groups: short-term anticoagulation after attempted conversion, with antiarrhythmic therapy to prevent atrial fibrillation recurrence, or long-term anticoagulation and rate control. After 19.6 months of follow-up, the annual incidence of death, stroke, transient ischemic attack, cardiopulmonary resuscitation, or thromboembolism was 5.5% in the rhythm-control group and 6.1% in the rate-control group (P > 0.2). Only 40% of the patients in the rhythm-control group maintained sinus rhythm at 1 year despite aggressive attempts. Even in the rhythm-control group, all thromboembolic end points occurred in patients while they were in atrial fibrillation.
A meta-analysis of these data was not performed because of the overwhelming influence the AFFIRM trial would exert given its large size compared with other trials. However, all the trials consistently showed no improvement in mortality or morbidity by aggressively controlling rhythm. Certainly, there are subgroups in which an aggressive strategy may be warranted, particularly in combination with aggressive anticoagulation. However, the evidence indicates that a strategy of rate control with antithrombotic therapy is as effective as strategies for rhythm control in many if not most patients with atrial fibrillation.

Anticoagulation

What Is the Evidence for Anticoagulating Patients in Chronic Atrial Fibrillation?

We identified 16 studies for inclusion in our analysis. Eleven (27-37) were reported in our previous systematic review (21). Three additional studies (38-40) were reported in a Cochrane Library review (41), and 1 was reported in a previous meta-analysis (42). For the current review, we identified 1 additional study (43).
All of the studies excluded patients with rheumatic valvular disease, for whom there is strong evidence that anticoagulation is indicated. Three trials were secondary prevention trials, enrolling patients who had already had a stroke or transient ischemic attack (28, 33, 43). The results of these studies were evaluated separately from those of the primary prevention studies. The Stroke Prevention in Atrial Fibrillation (SPAF) III investigators specifically recruited high-risk patients (31), and no trial specifically recruited patients at low risk for events. Several of the studies were terminated prematurely because of early proof of efficacy (27, 29, 31, 32, 37, 43) or publication of relevant results from other trials (33).
Figure 1 illustrates the absolute rates of stroke and hemorrhage for trials comparing warfarin or aspirin with control. In pooled analysis, warfarin was more efficacious than placebo for primary stroke prevention (OR, 0.31 [CI, 0.19 to 0.50]; P < 0.001), although suggestive evidence indicated that warfarin increased major bleeding (OR, 1.88 [CI, 0.88 to 4.00]; P = 0.10) (Table 1). The evidence from studies comparing aspirin with placebo suggested that stroke prevention was better with aspirin (OR, 0.68 [CI, 0.46 to 1.02]; P = 0.06); however, the evidence was inconclusive regarding the risk for major bleeding (OR, 0.82 [CI, 0.37 to 1.78]; P > 0.2). In direct comparison, moderate evidence indicated that fewer strokes occurred among patients taking warfarin than among those taking aspirin (OR, 0.66 [CI, 0.45 to 0.99]; P = 0.04), but evidence regarding bleeding risk was inconclusive (OR, 1.61 [CI, 0.75 to 3.44]; P > 0.2).
Figure 1.

Absolute rates of stroke and hemorrhage for trials comparing warfarin or aspirin with control.

Table 1. Meta-Analysis of Primary Prevention of Stroke in Atrial Fibrillation

Table 1. Meta-Analysis of Primary Prevention of Stroke in Atrial Fibrillation
In general, the evidence did not support the use of low-dose warfarin over several other treatments. Evidence suggested improved efficacy for stroke prevention with conventional-dose warfarin compared with low-dose warfarin whether the low-dose warfarin was given alone (OR, 0.52 [CI, 0.25 to 1.08]; P = 0.08) or combined with aspirin (OR, 0.44 [CI, 0.14 to 1.39]; P = 0.16). Evidence suggested increased bleeding risk with conventional-dose warfarin compared with low-dose warfarin alone (OR, 2.21 [CI, 0.67 to 7.25]; P = 0.19); however, the risk was not conclusively different when compared with low-dose warfarin combined with aspirin (OR, 1.14 [CI, 0.55 to 2.36]; P > 0.2). In the only study that compared low-dose warfarin with aspirin, the evidence was inconclusive regarding warfarin's efficacy (OR, 1.01 [CI, 0.49 to 2.06]; P > 0.2) and its bleeding risk (OR, 1.04 [CI, 0.43 to 2.48]; P > 0.2) (38).
For secondary prevention, we identified 2 trials evaluating warfarin or aspirin (28, 43). In 1 trial, patients were stratified by their eligibility for warfarin therapy (28). Criteria for ineligibility included chronic controlled or poorly controlled hypertension, chronic alcoholism, hemorrhagic retinopathy, previous intracranial hemorrhage, and poor compliance. Among the warfarin-eligible patients, warfarin was found to be more efficacious for stroke prevention (OR, 0.38 [CI, 0.22 to 0.66]; P = 0.001) but led to more episodes of major bleeding (OR, 4.1 [CI, 1.2 to 14]; P = 0.029) than placebo. For the warfarin-ineligible patients, no difference in efficacy (OR, 0.91 [CI, 0.66 to 1.3]; P > 0.2) or bleeding risk (OR, 1.4 [CI, 0.39 to 5.0]; P > 0.2) was demonstrated when aspirin was compared with placebo. Thus, the conclusions from this trial on secondary stroke prevention were consistent with those from the trials on primary prevention.
The other secondary prevention trial evaluated 2 intensities of warfarin anticoagulation (43). This trial was stopped early because the risk for major bleeding was found to be higher in the conventional-intensity warfarin group (international normalized ratio, 2.2 to 3.5) than in the low-intensity group (international normalized ratio, 1.5 to 2.1) (OR, 14.2 [CI, 0.78 to 257]; P = 0.07). The evidence for the efficacy of warfarin in ischemic stroke prevention was inconclusive (OR, 0.55 [CI, 0.5 to 6.2]; P > 0.2). The low number of participants in this trial precluded definitive conclusions.
Minimal data existed for the use of other antithrombotic regimens. In a single study (34), evidence was inconclusive regarding stroke risk for patients taking low-molecular-weight heparin compared with those receiving placebo (OR, 0.38 [CI, 0.072 to 2.0]; P > 0.2). In this small study, neither group had any major hemorrhagic events. In the single study comparing warfarin with indobufen for secondary stroke prevention, evidence suggested that warfarin decreased risk for recurrent stroke (OR, 0.57 [CI, 0.27 to 1.2]; P = 0.15) and increased bleeding risk (OR, 5.1 [CI, 0.59 to 44]; P = 0.14) (35).
We conclude that while insufficient evidence exists to support the use of low-dose warfarin, low-molecular-weight heparin, or newer antiplatelet agents to manage atrial fibrillation, evidence is sufficient to support the use of warfarin or aspirin, depending on patients' risks for stroke and bleeding. The evidence strongly supports the use of warfarin in patients with atrial fibrillation who have average or greater risk for stroke, unless there is a specific increased risk for bleeding. For patients with atrial fibrillation who have a lower risk for stroke, the evidence suggests that aspirin may be useful. For perspective, if a patient's baseline risk for stroke is 45 per 1000 patient-years, warfarin compared with placebo could prevent 30 strokes at the expense of only 6 additional major bleeding episodes. At that same stroke risk, aspirin compared with placebo could prevent 17 strokes without increasing the number of major hemorrhages. In patients with a lower risk for stroke, the absolute reduction in stroke rate with warfarin may not offset an increased risk for major bleeding.

What Is the Role of Transthoracic and Transesophageal Echocardiography in Identifying Patients in Permanent Atrial Fibrillation Who Should Receive Anticoagulation?

In our systematic review, we found no RCTs that directly assessed strategies for identifying appropriate candidates for antithrombotic therapy. However, indirect evidence is available from data in a few trials that were designed to address other questions. In the SPAF study, both left ventricular function and size of the left atrium on transthoracic echocardiography were independent predictors of thromboembolism (44). A strategy of stratification of thromboembolic risk including these 2 echocardiographic variables would alter therapy in 18% of the entire cohort and in 38% of those without clinical risk factors, compared with clinical risk factor stratification alone. In another study, investigators pooled individual patient results from 3 trials and showed that abnormal left ventricular function in otherwise low-risk patients increased the risk for stroke from 0.4% per year to 9.3% per year (45). In patients with high risk for stroke, abnormal left ventricular function increased the risk for stroke from 4.4% per year to greater than 15% per year. In contrast, left atrial size on M-mode echocardiography did not predict stroke.
Transesophageal echocardiography has been shown to identify features correlating with high thromboembolic risk, including left atrial thrombus (46-49), left atrial appendage size (47), left atrial appendage peak velocities (48, 49), spontaneous echocardiographic contrast (often called smoke) (47, 50, 51), left ventricular dysfunction (50), left ventricular hypertrophy (50), and complex aortic plaque (47-50). The SPAF III trial prospectively assessed the ability of transesophageal echocardiography to stratify patients with atrial fibrillation by risk (48). Independent risk factors for stroke included complex aortic plaque and left atrial abnormality, such as thrombus in the left atrial appendage, spontaneous echocardiographic contrast in the left atrium or left atrial appendage, or peak antegrade flow from the left atrial appendage. The stroke rates were 1.3% per year if neither risk factor was present, 7.8% per year if a left atrial abnormality was present, 12.0% per year if a complex aortic plaque was present, and 20.5% per year if both were present. Thus, transthoracic echocardiography can be used to stratify patients by risk on the basis of left ventricular function. Transesophageal echocardiography can also stratify patients by risk on the basis of left atrial abnormalities and aortic plaque.

Rate Control

What Is the Efficacy of Each Agent in the Control of Ventricular Rate in Atrial Fibrillation?

Our systematic review identified 54 trials assessing 17 agents used for rate control in atrial fibrillation (21). We concentrated on studies evaluating digoxin, calcium-channel blockers, and -blockers. Methods and outcome measures of these studies were deemed too heterogeneous for a quantitative summary. Main outcome measures included mean heart rate at rest, maximum heart rate with exercise, and distance or time walked on an exercise test. In addition to the heterogeneity of outcome measures, 2 other methodologic considerations were noted: The studies were small, ranging from 6 to 239 patients, and follow-up varied, ranging from 15 minutes to 8 weeks.
Comparisons of digoxin with placebo were inconsistent, particularly when tests were done during exercise (52-58). The nondihydropyridine calcium-channel blockers diltiazem and verapamil were effective compared with placebo (52, 59-65) or digoxin (64-72) in reducing the ventricular rate both at rest and during exercise in patients with atrial fibrillation. The efficacy of -blockers in the control of resting ventricular rate was agent specific. Atenolol (64, 72, 73), metoprolol (70), timolol (74), pindolol (73), and nadolol (75) were effective. The evidence on xamoterol (58, 60, 64, 76) was inconsistent. Celiprolol (77, 78) and labetalol (54) were ineffective. However, all -blockers tested were more effective than placebo in controlling ventricular rate during exercise in patients with atrial fibrillation (54, 58, 63, 64, 70, 77, 78). Of note, the evidence on exercise tolerance in patients taking -blockers compared with those taking placebo was inconsistent, indicating increased (58, 65, 70), decreased (74, 78), or similar (63) exercise tolerance. Combination therapy with digoxindiltiazem (52, 57, 79-81), digoxinverapamil (69, 82-85), digoxinxamoterol (76), digoxinnadolol (86), and digoxinbetaxolol (57, 79) was effective both at rest and with exercise. Labetalol, even in combination with digoxin, was ineffective at rest but effective with exercise (54). Other studies compared less common agents or were not placebo-controlled trials (87-101).
The side effects of rate-control agents were reported inconsistently. Most studies reported having a single patient or no patients with side effects. However, in 1 study, 3 of 14 patients given diltiazem experienced clinically significant side effects, including chest pain, dyspnea, and edema (52). In another, 3 of 18 patients receiving verapamil required drug withdrawal for liver toxicity or pneumonia (60). In a third study, 5 of 15 patients receiving atenolol required drug withdrawal, but the reasons were not given (62). Finally, 1 trial stopped digoxin therapy in 2 of 117 patients because of clinically significant arrhythmias (56). Since congestive heart failure was an exclusion criterion in many of the studies, the side effect profile in patients with congestive heart failure was not directly addressed.
Thus, the nondihydropyridine calcium-channel blockers, such as verapamil or diltiazem, and -blockers, such as atenolol and metoprolol, have been shown to control ventricular rate at rest and with exercise. Although patients' ability to tolerate these medications must be considered, both drug classes seem to have superior efficacy compared with digoxin. The evidence suggests that adding digoxin to a nondihydropyridine calcium-channel blocker or a -blocker may provide additional benefit over either drug alone.

Acute Conversion

What Is the Efficacy of Antiarrhythmic Agents Used for Acute Conversion of Atrial Fibrillation to Sinus Rhythm?

Our meta-analysis included 60 randomized clinical trials evaluating the use of 8 antiarrhythmic agents for acute conversion of nonpostoperative atrial fibrillation (21, 102). Because digoxin lacked efficacy compared with placebo (53, 55, 56) and -blockers and calcium-channel blockers were not definitely proven to be superior to placebo, studies that involved these agents or placebo were treated as having control arms. The studies evaluated heterogeneous patient samples, reflected by the conversion rates in the control groups, which ranged from 0% to 76%. Thus, the difference in absolute conversion rates among different antiarrhythmic agents is difficult to determine across studies.
Figure 2 illustrates the absolute rates of conversion for the 43 studies with control arms. In pooled analyses, we found strong evidence of efficacy for acute conversion of atrial fibrillation compared with controls for ibutilide (103-106), flecainide (94, 107-110), dofetilide (111-116), propafenone (94, 101, 117-130), and amiodarone (109, 112, 125, 128, 131-141), with moderate evidence for quinidine (94, 123) (Table 2). Insufficient evidence of efficacy was found for disopyramide (92) and sotalol (135, 142, 143).
Figure 2.

Proportions of patients who had successful pharmacologic intervention.

Table 2. Pooled Results for the Efficacy and Adverse Effects of Drugs Used in Acute Conversion of Atrial Fibrillation

Table 2. Pooled Results for the Efficacy and Adverse Effects of Drugs Used in Acute Conversion of Atrial Fibrillation
When we included 5 studies that also contained control arms, 22 studies directly compared antiarrhythmic agents. Because few studies had identical comparisons and most studies were small, the ability to construct a hierarchical order of efficacy was limited. However, the general tendency of the results paralleled those of the meta-analysis of studies with control arms. The evidence showed greater efficacy for flecainide compared with propafenone (OR, 3.5 [CI, 1.8 to 6.7]; P < 0.01) (94, 144, 145), sotalol (OR, 3.5 [CI, 1.4 to 9.1]; P = 0.002) (146), and procainamide (OR, 7.4 [CI, 1.7 to 42.9]; P < 0.01) (147). Similarly, ibutilide was more efficacious than sotalol (OR, 13.7 [CI, 5.8 to 35.4]; P < 0.01) (148) and procainamide (OR, 6.2 [CI, 2.5 to 15.8]; P < 0.01) (149). In other studies, propafenone was more efficacious than amiodarone (OR, 13.1 [CI, 2.1 to 79.6]; P < 0.002) (150), amiodarone was more efficacious than quinidine (OR, 4.5 [CI, 1.2 to 17.4]; P < 0.02) (99), and quinidine was more efficacious than sotalol (OR, 5.8 [CI, 2.4 to 14.2]; P < 0.01) (151, 152).
Three methodologic problems were noted in these studies. First, the studies were small, ranging from 11 to 239 patients. Second, the follow-up was short, usually less than 24 hours. Third, the duration of atrial fibrillation was variable. Some studies required an upper limit for duration as short as 24 hours, while other studies had no upper limit. These last 2 factors accounted for much of the heterogeneity of spontaneous conversion; the studies in which patients had shorter duration of atrial fibrillation and were followed for longer periods were more likely to have high spontaneous conversion rates. In the limited subgroup analyses possible, relative efficacy of the antiarrhythmic agents did not differ on the basis of duration of atrial fibrillation or length of follow-up.

What Is the Safety of Antiarrhythmic Therapy for Conversion of Atrial Fibrillation?

The major concern with starting antiarrhythmic therapy for atrial fibrillation is the potential to induce polymorphic ventricular tachycardia, often called torsades de pointes. The precise mechanism of induction of this arrhythmia is not clear, but it is associated with a marked prolongation of the cardiac action potential, which can be measured by the QT interval on the electrocardiogram (153). However, different agents can prolong the QT interval to similar degrees with different risks for torsades de pointes. The risk for torsades de pointes increases for patients with structural heart disease, hypokalemia, and bradycardia (153, 154).
Estimating the risk for ventricular arrhythmia is particularly important in deciding whether to initiate antiarrhythmic therapy under close inpatient monitoring or on an outpatient basis. Two studies investigating this question found the greatest incidence of arrhythmia within the first 24 hours (155) or 3 days (156) of therapy. Most patients in these studies had structural heart disease. Another study followed 172 patients, 82% of whom had normal ejection fractions; the researchers found no cases of significant arrhythmia in the first 4 days of therapy (157). Thus, current recommendations include a 1- to 3-day inpatient observation period after starting most antiarrhythmic agents for patients with atrial fibrillation (155, 156). Two exceptions were noted in a recent guideline (156): First, amiodarone can usually be given safely on an outpatient basis, and second, outpatient initiation of sotalol and disopyramide may be reasonable in patients without structural heart disease (left ventricular ejection fraction 0.45, coronary artery disease, valvular heart disease, or left ventricular hypertrophy), abnormal conduction system (sick sinus syndrome, atrioventricular conduction disturbances, or bundle-branch blocks), or long QT.
In our systematic review of RCTs, only 39 of the 60 clinical trials on the pharmacologic conversion of atrial fibrillation reported the incidence of ventricular arrhythmia, limiting the usefulness of these data (Table 2). Of those reported, no ventricular arrhythmias occurred with amiodarone (110, 125, 126, 128, 135-141, 147, 150, 158) or procainamide (149). The incidence was 3% or less for flecainide (94, 110, 124, 145-147, 159), propafenone (94, 117, 122, 126, 128, 136, 145, 150, 158), and sotalol (143, 146). Ventricular arrhythmias were noted in up to 9% of patients with ibutilide (104-106, 148, 149), and up to 12% of patients for quinidine (94, 152, 160, 161) and dofetilide (111-116).

What Are the Efficacy and Safety of Direct-Current Cardioversion?

Direct-current cardioversion of atrial fibrillation was first reported by Bernard Lown in 1963 (162). The efficacy of traditional, external, monophasic direct-current cardioversion in consecutive patients has consistently been found to be 80% to 85% (163-168). Applying direct-current cardioversion directly in the right atrium through percutaneous catheter has been shown to increase the efficacy to more than 90% (169, 170); however, the invasive nature of this procedure limits applicability. Biphasic defibrillators, which use less energy but apply both positive and negative currents, have also been shown to increase the efficacy of transthoracic cardioversion to more than 90% (168, 171, 172).
Ventricular tachycardia occurs rarely and was noted in only 1 patient in the trials in this review (170). In 1 study (169), transient atrioventricular node dysfunction occurred in 7 of 112 patients but lasted less than 15 seconds. One study found that moderate skin burns (with tenderness) occurred in about 40% of patients after external monophasic electrical cardioversion and severe burns (blistering) occurred in 2% (168). Biphasic waveforms decreased the incidence and severity of these burns.

What Is the Efficacy of Pharmacologic Treatment of Atrial Fibrillation before Electrical Cardioversion?

Of the 8 RCTs evaluating the efficacy of administering antiarrhythmic agents before direct-current cardioversion compared with direct-current cardioversion alone, 7 demonstrated no increased efficacy with the addition of quinidine, propafenone, or sotalol (128, 142, 173-177). One study demonstrated improved efficacy with use of ibutilide (178). Although starting an antiarrhythmic agent before direct-current cardioversion in an attempt to maintain sinus rhythm after cardioversion may be appropriate, the data do not support the routine use of an antiarrhythmic agent before direct-current cardioversion to improve the efficacy of restoring sinus rhythm.

What Is the Usefulness of Transesophageal Echocardiography in the Acute Conversion of Atrial Fibrillation?

In a pooled analysis of observational data, Moreyra and coworkers (179) estimated the risk for thromboembolism after cardioversion to be 0.33% in those who had received anticoagulation before cardioversion and 2.00% in those who had not. The risk for thromboembolism does not seem to differ between electrical cardioversion and pharmacologic conversion (180). At least 2 mechanisms may be responsible for the thromboembolic risk associated with conversion of atrial fibrillation. First, thrombi in the left atrium or the left atrial appendage that are present before conversion may embolize once atrial contraction resumes (181-183). Second, because both left atrial function and left atrial appendage function are impaired shortly after conversion, thrombus may develop after conversion (184-186).
Conventional recommendations include treating patients experiencing atrial fibrillation with warfarin, with a goal international normalized ratio of 2.0 to 3.0, for 3 weeks before cardioversion and for 4 weeks after conversion (187). From a pathophysiologic standpoint, this strategy could stabilize preexisting thrombi and prevent new thrombus formation. However, no clinical trials have directly compared this strategy with no anticoagulation or with anticoagulation of varying intensities or duration.
Given the high sensitivity and specificity of transesophageal echocardiography (TEE) to detect left atrial and left atrial appendage thrombus (188-190), this procedure could be used to stratify patients by risk before cardioversion. Initial experience using TEE to identify patients who could safely undergo cardioversion without anticoagulation found an unacceptably high embolic risk of 1.34% (179). However, no thromboembolic events occurred in 1 study of 236 patients that used a strategy of short-term anticoagulation (approximately 48 hours) and TEE for identification of existing thrombi before cardioversion with post-cardioversion anticoagulation (191). The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) study was a randomized clinical trial comparing a TEE-guided strategy with the conventional strategy in patients with atrial fibrillation lasting longer than 2 days (167). In the TEE-guided group, thrombus in the left atrium, left atrial appendage, or right atrium was identified in 76 of 619 patients (14%). These patients received at least 4 weeks of anticoagulation before any cardioversion attempt. The remaining patients without thrombus identified on TEE were converted immediately and received anticoagulation for at least 4 weeks afterward. The primary end point of stroke, transient ischemic attack, or peripheral embolism did not differ between the TEE-guided group and the conventional group (0.81% vs. 0.50%, respectively; P > 0.2). However, there was a significant difference in the composite end point of major and minor bleeding (2.9% for the TEE-guided group and 5.5% for the conventional group; P = 0.02). The low incidence of the primary end point in each arm of this trial underscores the efficacy of anticoagulation in settings with close monitoring of anticoagulation surrounding conversion. The recent Ludwigshafen Observational Cardioversion Study reproduced these low embolic rates and found no difference between patients treated with the TEE-guided approach and patients treated conventionally (0.8% for both groups) (192). Analysis of observational studies suggests that the TEE-guided approach may be cost-effective (193); however, the cost-effectiveness analysis of the ACUTE trial has not been published.
Overall, the literature suggests that TEE-guided conversion using short-term preconversion anticoagulation and at least 3 weeks of appropriate postconversion anticoagulation may be an effective, safe alternative to the conventional approach.

What Is the Role of Transthoracic Echocardiography in Identifying Likelihood of Successful Conversion of Atrial Fibrillation?

We addressed the ability of echocardiography to predict the likelihood of successful conversion by reviewing randomized clinical trials that reported outcomes relative to left atrial diameter. Of the 46 studies evaluating acute pharmacologic conversion that we identified in our comprehensive search (21), only 6 gave information relating left atrial diameter on echocardiography to success of conversion. Five of these studies found an inverse relation between left atrial size and success of conversion (99, 105, 128, 194, 195). The final study in this group found no difference in left atrial size between patients with successful and unsuccessful conversion (94). The fact that the left atrium was smaller and conversion less likely in the placebo group compared with the treatment groups may have confounded this last study. Because the methods for relating left atrial size to cardioversion success were not consistent across the studies, combining the data is not helpful. Qualitatively, the evidence suggests that the likelihood of successful pharmacologic cardioversion is related to left atrial size as measured by echocardiography.

Maintenance of Sinus Rhythm

What Is the Efficacy of Each Antiarrhythmic Agent for the Maintenance of Sinus Rhythm after Successful Conversion of Atrial Fibrillation to Sinus Rhythm?

Our meta-analysis identified 30 RCTs evaluating 7 antiarrhythmic agents used for maintenance of sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Our previous meta-analysis included 28 of these trials (21). In the 18 trials with a control arm, we found strong evidence of efficacy for amiodarone, propafenone, disopyramide, and sotalol (Table 3 and Figure 3). Moderate evidence was found for flecainide, quinidine, and azimilide.

Table 3. Pooled Results of Randomized, Controlled Trials of Drugs for Maintenance of Sinus Rhythm after Conversion of Atrial Fibrillation

Table 3. Pooled Results of Randomized, Controlled Trials of Drugs for Maintenance of Sinus Rhythm after Conversion of Atrial Fibrillation
Figure 3.

Proportions of patients who had successful maintenance of sinus rhythm.

Our search identified 15 studies that directly compared antiarrhythmic agents. Only 3 studies showed a statistically significant difference between agents. Two trials showed superior efficacy for amiodarone compared with sotalol or propafenone (196, 197). In 1 trial, propafenone had greater efficacy than quinidine (100).
As with the studies evaluating acute conversion, 3 methodologic problems were noted. First, the studies were relatively small, ranging from 12 to 289 patients. Second, the duration of atrial fibrillation in the selected patients varied. Precise information on this duration is limited. Some studies excluded patients who had had atrial fibrillation for more than 48 hours, whereas other studies had no upper limit for duration. Third, the length of follow-up was short, ranging from 1 to 18 months. While subgroup analyses found only minimal differences in relative efficacy based on length of follow-up, these analyses were limited by the small number of studies for each comparison.

What Is the Long-Term Safety of Antiarrhythmic Therapy?

The safety of long-term antiarrhythmic therapy has been questioned. The Cardiac Arrhythmia Suppression Trial (198) found an increased mortality with class IC agents (for example, flecainide) in patients with nonsustained ventricular tachycardia after myocardial infarction. In addition, a meta-analysis of RCTs found increased mortality associated with quinidine (199). More recently, as discussed previously, the AFFIRM trial found a nonsignificant increase in mortality in the rhythm-control group compared with the rate-control group (hazard ratio, 1.15 [CI, 0.99 to 1.34]; P = 0.08). The relatively short follow-up in the clinical trials (<3.5 years) limits any longer-term riskbenefit evaluations of safety and efficacy.
Antiarrhythmic therapy may induce serious ventricular tachycardia, in particular torsades de pointes. Only 18 of 30 studies evaluating maintenance of sinus rhythm reported the incidence of ventricular arrhythmia (Table 3). There were no reported ventricular arrhythmias in studies evaluating amiodarone (134, 137, 196, 197), flecainide (200-203), or disopyramide (204). Ventricular arrhythmias were noted in 0% to 3% of patients receiving propafenone (100, 128, 196, 202, 204-206, 207, 208), 0% to 5% of those receiving sotalol (151, 196, 197, 205, 208, 209-211), 0% to 12% of those receiving quinidine (100, 151, 174, 200, 201, 209, 211), and 1% of those receiving azimilide (212).
These trials had a widely varying incidence of other side effects that prompted cessation or decreased dosage of the antiarrhythmic agent. Such side effects occurred in up to 58% of patients taking quinidine (213), 55% of those taking disopyramide (204), 20% of those taking flecainide (201), 18% of those taking propafenone (202), and 13% of those taking sotalol (142). Although the risk for torsades de pointes associated with amiodarone is small, this drug often raises concern because of its potential for causing other adverse effects. In the 201 patients assigned to receive amiodarone in the Canadian Trial of Atrial Fibrillation Investigators (196), other cardiac side effects included unacceptable prolongation of the QT interval (1 patient), heart failure (2 patients), and serious bradyarrhythmias (6 patients). Incidences were similar among the patients treated with propafenone or sotalol. In this trial, amiodarone was discontinued more frequently for noncardiac side effects, including suspected pulmonary toxicity (4 patients), hypothyroidism (2 patients), hyperthyroidism (1 patient), and other reasons (2 patients). Noncardiac side effects prompted discontinuation of sotalol or propafenone in only 3 patients.
Thus, safety and side effects are critical factors when considering whether to start or maintain antiarrhythmic therapy. Amiodarone appears to be relatively safe from a cardiac perspective but has a substantial profile of noncardiac side effects. The other antiarrhythmic agents require careful consideration in patients with structural heart disease because of the risk for proarrhythmia. In particular, flecainide is not indicated in patients with coronary artery disease.

What Is the Role of Echocardiography in Identifying the Likelihood of Successful Maintenance of Sinus Rhythm?

Of the 30 studies evaluating maintenance of sinus rhythm in our original review, only 2 reported on the relation between left atrial size and efficacy. Bellandi and colleagues (214) found a statistically significant relationship between recurrent atrial fibrillation and left atrial size in all 3 treatment groups (propafenone, sotalol, and placebo). Van Gelder and associates (203) reported that, after controlling for New York Heart Association class and flecainide treatment, the predictive power of left atrial size for efficacy did not reach statistical significance. Overall, the paucity of evidence precludes strong conclusions regarding the association between left atrial size and maintenance of sinus rhythm after conversion of atrial fibrillation.
Little evidence exists regarding the role of TEE in identifying patients with a high likelihood of maintaining sinus rhythm. One study found high left atrial appendage velocities on TEE to be the only echocardiographic variable predictive of patients remaining in sinus rhythm for 1 year after cardioversion (215).

Conclusion

Substantial evidence exists to provide guidance in management of patients with atrial fibrillation. Recent trials have shown similar outcomes for patients treated with a rhythm-control strategy or a rate-control strategy. Warfarin significantly reduces stroke risk in patients unless the embolic risk is low or a contraindication to anticoagulation exists. -Blockers and calcium-channel blockers are superior to digoxin for rate control when patients do not have contraindications to these therapies. Many antiarrhythmic agents are superior to placebo for acute conversion. Some agents are efficacious for maintenance of sinus rhythm, but side effect profile should be considered in deciding whether to use antiarrhythmic therapy and in choosing an agent. Finally, echocardiography is useful in stratifying risk for thromboembolism and may be useful in predicting success for conversion of atrial fibrillation and maintenance of sinus rhythm.

References

  1. Bialy
    D
    ,  
    Lehmann
    MH
    ,  
    Schumacher
    DN
    ,  
    Steinman
    RT
    ,  
    Meissner
    MD
    .  
    Hospitalization for arrhythmias in the United States: importance of atrial fibrillation [Abstract]
    J Am Coll Cardiol
    1992
    19
    41A
  2. Ostrander
    LD
    Jr
    ,  
    Brandt
    RL
    ,  
    Kjelsberg
    MO
    ,  
    Epstein
    FH
    .  
    Electrocardiographic Findings among the Adult Population of a Total Natural Community, Tecumseh, Michigan
    Circulation
    1965
    31
    888
    98
    PubMed
    CrossRef
    PubMed
  3. Flegel
    KM
    ,  
    Shipley
    MJ
    ,  
    Rose
    G
    .  
    Risk of stroke in non-rheumatic atrial fibrillation
    Lancet
    1987
    1
    526
    9
    PubMed
    CrossRef
    PubMed
  4. Wolf
    PA
    ,  
    Abbott
    RD
    ,  
    Kannel
    WB
    .  
    Atrial fibrillation as an independent risk factor for stroke: the Framingham Study
    Stroke
    1991
    22
    983
    8
    PubMed
    CrossRef
    PubMed
  5. Furberg
    CD
    ,  
    Psaty
    BM
    ,  
    Manolio
    TA
    ,  
    Gardin
    JM
    ,  
    Smith
    VE
    ,  
    Rautaharju
    PM
    .  
    Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
    Am J Cardiol
    1994
    74
    236
    41
    PubMed
    CrossRef
    PubMed
  6. Go
    AS
    ,  
    Hylek
    EM
    ,  
    Phillips
    KA
    ,  
    Chang
    Y
    ,  
    Henault
    LE
    ,  
    Selby
    JV
    ,  
    .  
    Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    JAMA
    2001
    285
    2370
    5
    PubMed
    CrossRef
    PubMed
  7. Wolf
    PA
    ,  
    Abbott
    RD
    ,  
    Kannel
    WB
    .  
    Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study
    Arch Intern Med
    1987
    147
    1561
    4
    PubMed
    CrossRef
    PubMed
  8. Krahn
    AD
    ,  
    Manfreda
    J
    ,  
    Tate
    RB
    ,  
    Mathewson
    FA
    ,  
    Cuddy
    TE
    .  
    The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study
    Am J Med
    1995
    98
    476
    84
    PubMed
    CrossRef
    PubMed
  9. Psaty
    BM
    ,  
    Manolio
    TA
    ,  
    Kuller
    LH
    ,  
    Kronmal
    RA
    ,  
    Cushman
    M
    ,  
    Fried
    LP
    ,  
    .  
    Incidence of and risk factors for atrial fibrillation in older adults
    Circulation
    1997
    96
    2455
    61
    PubMed
    CrossRef
    PubMed
  10. Kannel
    WB
    ,  
    Abbott
    RD
    ,  
    Savage
    DD
    ,  
    McNamara
    PM
    .  
    Coronary heart disease and atrial fibrillation: the Framingham Study
    Am Heart J
    1983
    106
    389
    96
    PubMed
    CrossRef
    PubMed
  11. Brand
    FN
    ,  
    Abbott
    RD
    ,  
    Kannel
    WB
    ,  
    Wolf
    PA
    .  
    Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study
    JAMA
    1985
    254
    3449
    53
    PubMed
    CrossRef
    PubMed
  12. Kopecky
    SL
    ,  
    Gersh
    BJ
    ,  
    McGoon
    MD
    ,  
    Whisnant
    JP
    ,  
    Holmes
    DR
    Jr
    ,  
    Ilstrup
    DM
    ,  
    .  
    The natural history of lone atrial fibrillation. A population-based study over three decades
    N Engl J Med
    1987
    317
    669
    74
    PubMed
    CrossRef
    PubMed
  13. Wolf
    PA
    ,  
    Dawber
    TR
    ,  
    Thomas
    HE
    Jr
    ,  
    Kannel
    WB
    .  
    Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study
    Neurology
    1978
    28
    973
    7
    PubMed
    CrossRef
    PubMed
  14. Wolf
    PA
    ,  
    Abbott
    RD
    ,  
    Kannel
    WB
    .  
    Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study
    Arch Intern Med
    1987
    147
    1561
    4
    PubMed
    CrossRef
    PubMed
  15. Levy
    S
    ,  
    Maarek
    M
    ,  
    Coumel
    P
    ,  
    Guize
    L
    ,  
    Lekieffre
    J
    ,  
    Medvedowsky
    JL
    ,  
    .  
    Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists
    Circulation
    1999
    99
    3028
    35
    PubMed
    CrossRef
    PubMed
  16. Hart
    RG
    ,  
    Pearce
    LA
    ,  
    Rothbart
    RM
    ,  
    McAnulty
    JH
    ,  
    Asinger
    RW
    ,  
    Halperin
    JL
    .  
    Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators
    J Am Coll Cardiol
    2000
    35
    183
    7
    PubMed
    CrossRef
    PubMed
  17. Hamer
    ME
    ,  
    Blumenthal
    JA
    ,  
    McCarthy
    EA
    ,  
    Phillips
    BG
    ,  
    Pritchett
    EL
    .  
    Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia
    Am J Cardiol
    1994
    74
    826
    9
    PubMed
    CrossRef
    PubMed
  18. Gage
    BF
    ,  
    Cardinalli
    AB
    ,  
    Owens
    DK
    .  
    The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life
    Arch Intern Med
    1996
    156
    1829
    36
    PubMed
    CrossRef
    PubMed
  19. Protheroe
    J
    ,  
    Fahey
    T
    ,  
    Montgomery
    AA
    ,  
    Peters
    TJ
    .  
    The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis
    BMJ
    2000
    320
    1380
    4
    PubMed
    CrossRef
    PubMed
  20. Fuster
    V
    ,  
    Ryden
    LE
    ,  
    Asinger
    RW
    ,  
    Cannom
    DS
    ,  
    Crijns
    HJ
    ,  
    Frye
    RL
    ,  
    .  
    ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in Collaboration with the North American Society of Pacing and Electrophysiology
    J Am Coll Cardiol
    2001
    38
    1231
    66
    PubMed
    CrossRef
    PubMed
  21. McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, et al. Evidence Report on Management of New Onset Atrial Fibrillation. Agency for Healthcare Research and Quality publication no. AHRQ 01-E026. Rockville, MD: Agency for Healthcare Research and Quality; January 2001.
  22. Deeks
    JJ
    ,  
    Altman
    DG
    ,  
    Bradburn
    MJ
    .  
    Statistical methods for examining and combining results from several studies in meta-analysis. in: Systematic Reviews in Health Care: Meta-Analysis in Context
    London
    BMJ Books
    2001
  23. DerSimonian
    R
    ,  
    Laird
    N
    .  
    Meta-analysis in clinical trials
    Control Clin Trials
    1986
    7
    177
    88
    PubMed
    CrossRef
    PubMed
  24. Wyse
    DG
    ,  
    Waldo
    AL
    ,  
    DiMarco
    JP
    ,  
    Domanski
    MJ
    ,  
    Rosenberg
    Y
    ,  
    Schron
    EB
    ,  
    .  
    A comparison of rate control and rhythm control in patients with atrial fibrillation
    N Engl J Med
    2002
    347
    1825
    33
    PubMed
    CrossRef
    PubMed
  25. Van Gelder
    IC
    ,  
    Hagens
    VE
    ,  
    Bosker
    HA
    ,  
    Kingma
    JH
    ,  
    Kamp
    O
    ,  
    Kingma
    T
    ,  
    .  
    A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation
    N Engl J Med
    2002
    347
    1834
    40
    PubMed
    CrossRef
    PubMed
  26. Hohnloser
    SH
    ,  
    Kuck
    KH
    ,  
    Lilienthal
    J
    .  
    Rhythm or rate control in atrial fibrillationPharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial
    Lancet
    2000
    356
    1789
    94
    PubMed
    CrossRef
    PubMed
  27. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators
    N Engl J Med
    1990
    323
    1505
    11
    PubMed
    CrossRef
    PubMed
  28. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group
    Lancet
    1993
    342
    1255
    62
    PubMed
    PubMed
  29. Stroke Prevention in Atrial Fibrillation Study. Final results
    Circulation
    1991
    84
    527
    39
    PubMed
    CrossRef
    PubMed
  30. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study
    Lancet
    1994
    343
    687
    91
    PubMed
    PubMed
  31. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
    Lancet
    1996
    348
    633
    8
    PubMed
    CrossRef
    PubMed
  32. Petersen
    P
    ,  
    Boysen
    G
    ,  
    Godtfredsen
    J
    ,  
    Andersen
    ED
    ,  
    Andersen
    B
    .  
    Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
    Lancet
    1989
    1
    175
    9
    PubMed
    CrossRef
    PubMed
  33. Gullov
    AL
    ,  
    Koefoed
    BG
    ,  
    Petersen
    P
    ,  
    Pedersen
    TS
    ,  
    Andersen
    ED
    ,  
    Godtfredsen
    J
    ,  
    .  
    Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
    Arch Intern Med
    1998
    158
    1513
    21
    PubMed
    CrossRef
    PubMed
  34. Harenberg
    J
    ,  
    Weuster
    B
    ,  
    Pfitzer
    M
    ,  
    Dempfle
    CE
    ,  
    Stehle
    G
    ,  
    Kubler
    W
    ,  
    .  
    Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin
    Semin Thromb Hemost
    1993
    19
    116
    21
    PubMed
    PubMed
  35. Morocutti
    C
    ,  
    Amabile
    G
    ,  
    Fattapposta
    F
    ,  
    Nicolosi
    A
    ,  
    Matteoli
    S
    ,  
    Trappolini
    M
    ,  
    .  
    Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators
    Stroke
    1997
    28
    1015
    21
    PubMed
    CrossRef
    PubMed
  36. Ezekowitz
    MD
    ,  
    Bridgers
    SL
    ,  
    James
    KE
    ,  
    Carliner
    NH
    ,  
    Colling
    CL
    ,  
    Gornick
    CC
    ,  
    .  
    Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators
    N Engl J Med
    1992
    327
    1406
    12
    PubMed
    CrossRef
    PubMed
  37. Connolly
    SJ
    ,  
    Laupacis
    A
    ,  
    Gent
    M
    ,  
    Roberts
    RS
    ,  
    Cairns
    JA
    ,  
    Joyner
    C
    .  
    Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
    J Am Coll Cardiol
    1991
    18
    349
    55
    PubMed
    CrossRef
    PubMed
  38. Hellemons
    BS
    ,  
    Langenberg
    M
    ,  
    Lodder
    J
    ,  
    Vermeer
    F
    ,  
    Schouten
    HJ
    ,  
    Lemmens
    T
    ,  
    .  
    Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin
    BMJ
    1999
    319
    958
    64
    PubMed
    CrossRef
    PubMed
  39. Pengo
    V
    ,  
    Zasso
    A
    ,  
    Barbero
    F
    ,  
    Banzato
    A
    ,  
    Nante
    G
    ,  
    Parissenti
    L
    ,  
    .  
    Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation
    Am J Cardiol
    1998
    82
    433
    7
    PubMed
    CrossRef
    PubMed
  40. Posada
    IS
    ,  
    Barriales
    V
    .  
    Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group
    Am Heart J
    1999
    138
    137
    43
    PubMed
    CrossRef
    PubMed
  41. Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev. 2001; (1):CD001938. [PMID: 11279741]
  42. Segal
    JB
    ,  
    McNamara
    RL
    ,  
    Miller
    MR
    ,  
    Kim
    N
    ,  
    Goodman
    SN
    ,  
    Powe
    NR
    ,  
    .  
    Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs
    J Gen Intern Med
    2000
    15
    56
    67
    PubMed
    CrossRef
    PubMed
  43. Yamaguchi
    T
    .  
    Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group
    Stroke
    2000
    31
    817
    21
    PubMed
    CrossRef
    PubMed
  44. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators
    Ann Intern Med
    1992
    116
    6
    12
    CrossRef
    PubMed
  45. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials
    Arch Intern Med
    1998
    158
    1316
    20
    PubMed
    CrossRef
    PubMed
  46. Leung
    DY
    ,  
    Davidson
    PM
    ,  
    Cranney
    GB
    ,  
    Walsh
    WF
    .  
    Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram
    Am J Cardiol
    1997
    79
    626
    9
    PubMed
    CrossRef
    PubMed
  47. Stollberger
    C
    ,  
    Chnupa
    P
    ,  
    Kronik
    G
    ,  
    Brainin
    M
    ,  
    Finsterer
    J
    ,  
    Schneider
    B
    ,  
    .  
    Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi
    Ann Intern Med
    1998
    128
    630
    8
    CrossRef
    PubMed
  48. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography
    Ann Intern Med
    1998
    128
    639
    47
    CrossRef
    PubMed
  49. Zabalgoitia
    M
    ,  
    Halperin
    JL
    ,  
    Pearce
    LA
    ,  
    Blackshear
    JL
    ,  
    Asinger
    RW
    ,  
    Hart
    RG
    .  
    Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators
    J Am Coll Cardiol
    1998
    31
    1622
    6
    PubMed
    CrossRef
    PubMed
  50. Jones
    EF
    ,  
    Calafiore
    P
    ,  
    McNeil
    JJ
    ,  
    Tonkin
    AM
    ,  
    Donnan
    GA
    .  
    Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke
    Am J Cardiol
    1996
    78
    425
    9
    PubMed
    CrossRef
    PubMed
  51. Leung
    DY
    ,  
    Black
    IW
    ,  
    Cranney
    GB
    ,  
    Hopkins
    AP
    ,  
    Walsh
    WF
    .  
    Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation
    J Am Coll Cardiol
    1994
    24
    755
    62
    PubMed
    CrossRef
    PubMed
  52. Lewis
    RV
    ,  
    Laing
    E
    ,  
    Moreland
    TA
    ,  
    Service
    E
    ,  
    McDevitt
    DG
    .  
    A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation
    Eur Heart J
    1988
    9
    279
    83
    PubMed
    CrossRef
    PubMed
  53. Falk
    RH
    ,  
    Knowlton
    AA
    ,  
    Bernard
    SA
    ,  
    Gotlieb
    NE
    ,  
    Battinelli
    NJ
    .  
    Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial
    Ann Intern Med
    1987
    106
    503
    6
    CrossRef
    PubMed
  54. Wong
    CK
    ,  
    Lau
    CP
    ,  
    Leung
    WH
    ,  
    Cheng
    CH
    .  
    Usefulness of labetalol in chronic atrial fibrillation
    Am J Cardiol
    1990
    66
    1212
    5
    PubMed
    CrossRef
    PubMed
  55. Jordaens
    L
    ,  
    Trouerbach
    J
    ,  
    Calle
    P
    ,  
    Tavernier
    R
    ,  
    Derycke
    E
    ,  
    Vertongen
    P
    ,  
    .  
    Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo
    Eur Heart J
    1997
    18
    643
    8
    PubMed
    CrossRef
    PubMed
  56. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group
    Eur Heart J
    1997
    18
    649
    54
    PubMed
    CrossRef
    PubMed
  57. Koh
    KK
    ,  
    Kwon
    KS
    ,  
    Park
    HB
    ,  
    Baik
    SH
    ,  
    Park
    SJ
    ,  
    Lee
    KH
    ,  
    .  
    Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation
    Am J Cardiol
    1995
    75
    88
    90
    PubMed
    CrossRef
    PubMed
  58. Ang
    EL
    ,  
    Chan
    WL
    ,  
    Cleland
    JG
    ,  
    Moore
    D
    ,  
    Krikler
    SJ
    ,  
    Alexander
    ND
    ,  
    .  
    Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation
    Br Heart J
    1990
    64
    256
    60
    PubMed
    CrossRef
    PubMed
  59. Goldenberg
    IF
    ,  
    Lewis
    WR
    ,  
    Dias
    VC
    ,  
    Heywood
    JT
    ,  
    Pedersen
    WR
    .  
    Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure
    Am J Cardiol
    1994
    74
    884
    9
    PubMed
    CrossRef
    PubMed
  60. Ellenbogen
    KA
    ,  
    Dias
    VC
    ,  
    Plumb
    VJ
    ,  
    Heywood
    JT
    ,  
    Mirvis
    DM
    .  
    A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study
    J Am Coll Cardiol
    1991
    18
    891
    7
    PubMed
    CrossRef
    PubMed
  61. Salerno
    DM
    ,  
    Dias
    VC
    ,  
    Kleiger
    RE
    ,  
    Tschida
    VH
    ,  
    Sung
    RJ
    ,  
    Sami
    M
    ,  
    .  
    Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group
    Am J Cardiol
    1989
    63
    1046
    51
    PubMed
    CrossRef
    PubMed
  62. Lundstrom
    T
    ,  
    Ryden
    L
    .  
    Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil
    J Am Coll Cardiol
    1990
    16
    86
    90
    PubMed
    CrossRef
    PubMed
  63. Lundstrom
    T
    ,  
    Moor
    E
    ,  
    Ryden
    L
    .  
    Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation
    Am Heart J
    1992
    124
    917
    23
    PubMed
    CrossRef
    PubMed
  64. Lewis
    RV
    ,  
    McMurray
    J
    ,  
    McDevitt
    DG
    .  
    Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation
    J Cardiovasc Pharmacol
    1989
    13
    1
    6
    PubMed
    CrossRef
    PubMed
  65. Panidis
    IP
    ,  
    Morganroth
    J
    ,  
    Baessler
    C
    .  
    Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis
    Am J Cardiol
    1983
    52
    1197
    201
    PubMed
    CrossRef
    PubMed
  66. Schreck
    DM
    ,  
    Rivera
    AR
    ,  
    Tricarico
    VJ
    .  
    Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin
    Ann Emerg Med
    1997
    29
    135
    40
    PubMed
    CrossRef
    PubMed
  67. Lewis
    RV
    ,  
    Irvine
    N
    ,  
    McDevitt
    DG
    .  
    Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem
    Eur Heart J
    1988
    9
    777
    81
    PubMed
    CrossRef
    PubMed
  68. Lewis
    RV
    ,  
    Laing
    E
    ,  
    Moreland
    TA
    ,  
    Service
    E
    ,  
    McDevitt
    DG
    .  
    A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation
    Eur Heart J
    1988
    9
    279
    83
    PubMed
    CrossRef
    PubMed
  69. Pomfret
    SM
    ,  
    Beasley
    CR
    ,  
    Challenor
    V
    ,  
    Holgate
    ST
    .  
    Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation
    Clin Sci (Lond)
    1988
    74
    351
    7
    PubMed
    CrossRef
    PubMed
  70. Ahuja
    RC
    ,  
    Sinha
    N
    ,  
    Saran
    RK
    ,  
    Jain
    AK
    ,  
    Hasan
    M
    .  
    Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosisa randomised cross-over study
    Int J Cardiol
    1989
    25
    325
    31
    PubMed
    CrossRef
    PubMed
  71. Botto
    GL
    ,  
    Bonini
    W
    ,  
    Broffoni
    T
    .  
    Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil
    Clin Cardiol
    1998
    21
    837
    40
    PubMed
    CrossRef
    PubMed
  72. Farshi
    R
    ,  
    Kistner
    D
    ,  
    Sarma
    JS
    ,  
    Longmate
    JA
    ,  
    Singh
    BN
    .  
    Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens
    J Am Coll Cardiol
    1999
    33
    304
    10
    PubMed
    CrossRef
    PubMed
  73. Channer
    KS
    ,  
    James
    MA
    ,  
    MacConnell
    T
    ,  
    Rees
    JR
    .  
    Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity
    Br J Clin Pharmacol
    1994
    37
    53
    7
    PubMed
    CrossRef
    PubMed
  74. Sweany
    AE
    ,  
    Moncloa
    F
    ,  
    Vickers
    FF
    ,  
    Zupkis
    RV
    .  
    Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias
    Clin Pharmacol Ther
    1985
    37
    124
    7
    PubMed
    CrossRef
    PubMed
  75. DiBianco
    R
    ,  
    Morganroth
    J
    ,  
    Freitag
    JA
    ,  
    Ronan
    JA
    Jr
    ,  
    Lindgren
    KM
    ,  
    Donohue
    DJ
    ,  
    .  
    Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin
    Am Heart J
    1984
    108
    1121
    7
    PubMed
    CrossRef
    PubMed
  76. Lawson-Matthew
    PJ
    ,  
    McLean
    KA
    ,  
    Dent
    M
    ,  
    Austin
    CA
    ,  
    Channer
    KS
    .  
    Xamoterol improves the control of chronic atrial fibrillation in elderly patients
    Age Ageing
    1995
    24
    321
    5
    PubMed
    CrossRef
    PubMed
  77. Myers
    J
    ,  
    Atwood
    JE
    ,  
    Sullivan
    M
    ,  
    Forbes
    S
    ,  
    Friis
    R
    ,  
    Pewen
    W
    ,  
    .  
    Perceived exertion and gas exchange after calcium and -blockade in atrial fibrillation
    J Appl Physiol
    1987
    63
    97
    104
    PubMed
    PubMed
  78. Lin
    SK
    ,  
    Morganroth
    J
    ,  
    Heng
    M
    ,  
    Rubler
    S
    ,  
    Baird
    W
    ,  
    Atwood
    JE
    ,  
    .  
    Effect of orally administered celiprolol in patients with chronic atrial fibrillation
    J Cardiovasc Pharmacol
    1986
    8
    S112
    5
    PubMed
    CrossRef
    PubMed
  79. Koh
    KK
    ,  
    Song
    JH
    ,  
    Kwon
    KS
    ,  
    Park
    HB
    ,  
    Baik
    SH
    ,  
    Park
    YS
    ,  
    .  
    Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study
    Int J Cardiol
    1995
    52
    167
    74
    PubMed
    CrossRef
    PubMed
  80. Wattanasuwan
    N
    ,  
    Khan
    IA
    ,  
    Mehta
    NJ
    ,  
    Arora
    P
    ,  
    Singh
    N
    ,  
    Vasavada
    BC
    ,  
    .  
    Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone
    Chest
    2001
    119
    502
    6
    PubMed
    CrossRef
    PubMed
  81. Schreck
    DM
    ,  
    Rivera
    AR
    ,  
    Tricarico
    VJ
    .  
    Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin
    Ann Emerg Med
    1997
    29
    135
    40
    PubMed
    CrossRef
    PubMed
  82. Brodsky
    MA
    ,  
    Orlov
    MV
    ,  
    Capparelli
    EV
    ,  
    Allen
    BJ
    ,  
    Iseri
    LT
    ,  
    Ginkel
    M
    ,  
    .  
    Magnesium therapy in new-onset atrial fibrillation
    Am J Cardiol
    1994
    73
    1227
    9
    PubMed
    CrossRef
    PubMed
  83. Channer
    KS
    ,  
    Papouchado
    M
    ,  
    James
    MA
    ,  
    Pitcher
    DW
    ,  
    Rees
    JR
    .  
    Towards improved control of atrial fibrillation
    Eur Heart J
    1987
    8
    141
    7
    PubMed
    CrossRef
    PubMed
  84. Stern
    EH
    ,  
    Pitchon
    R
    ,  
    King
    BD
    ,  
    Guerrero
    J
    ,  
    Schneider
    RR
    ,  
    Wiener
    I
    .  
    Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation
    Chest
    1982
    81
    308
    11
    PubMed
    CrossRef
    PubMed
  85. Lang
    R
    ,  
    Klein
    HO
    ,  
    Di Segni
    E
    ,  
    Gefen
    J
    ,  
    Sareli
    P
    ,  
    Libhaber
    C
    ,  
    .  
    Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study
    Am Heart J
    1983
    105
    820
    5
    PubMed
    CrossRef
    PubMed
  86. Zoble
    RG
    ,  
    Brewington
    J
    ,  
    Olukotun
    AY
    ,  
    Gore
    R
    .  
    Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation
    Am J Cardiol
    1987
    60
    39D
    45D
    PubMed
    CrossRef
    PubMed
  87. Smit
    AJ
    ,  
    Scaf
    AH
    ,  
    van Essen
    LH
    ,  
    Lie
    KI
    ,  
    Wesseling
    H
    .  
    Digoxin infusion versus bolus injection in rapid atrial fibrillation: relation between serum level and response
    Eur J Clin Pharmacol
    1990
    38
    335
    41
    PubMed
    CrossRef
    PubMed
  88. Hays
    JV
    ,  
    Gilman
    JK
    ,  
    Rubal
    BJ
    .  
    Effect of magnesium sulfate on ventricular rate control in atrial fibrillation
    Ann Emerg Med
    1994
    24
    61
    4
    PubMed
    CrossRef
    PubMed
  89. Roth
    A
    ,  
    Kaluski
    E
    ,  
    Felner
    S
    ,  
    Heller
    K
    ,  
    Laniado
    S
    .  
    Clonidine for patients with rapid atrial fibrillation
    Ann Intern Med
    1992
    116
    388
    90
    CrossRef
    PubMed
  90. Scardi
    S
    ,  
    Humar
    F
    ,  
    Pandullo
    C
    ,  
    Poletti
    A
    .  
    Oral clonidine for heart rate control in chronic atrial fibrillation [Letter]
    Lancet
    1993
    341
    1211
    2
    PubMed
    CrossRef
    PubMed
  91. Lok
    NS
    ,  
    Lau
    CP
    .  
    Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol
    Chest
    1997
    111
    934
    40
    PubMed
    CrossRef
    PubMed
  92. Boudonas
    G
    ,  
    Lefkos
    N
    ,  
    Efthymiadis
    AP
    ,  
    Styliadis
    IG
    ,  
    Tsapas
    G
    .  
    Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias
    Acta Cardiol
    1995
    50
    125
    34
    PubMed
    PubMed
  93. Suttorp
    MJ
    ,  
    Kingma
    JH
    ,  
    Jessurun
    ER
    ,  
    Lie-A-Huen
    L
    ,  
    van Hemel
    NM
    ,  
    Lie
    KI
    .  
    The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm
    J Am Coll Cardiol
    1990
    16
    1722
    7
    PubMed
    CrossRef
    PubMed
  94. Kingma
    JH
    ,  
    Suttorp
    MJ
    .  
    Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil
    Am J Cardiol
    1992
    70
    56A
    60A
    PubMed
    CrossRef
    PubMed
  95. Dahlstrm
    CG
    ,  
    Edvardsson
    N
    ,  
    Nasheng
    C
    ,  
    Olsson
    SB
    .  
    Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation
    Clin Cardiol
    1992
    15
    280
    4
    PubMed
    CrossRef
    PubMed
  96. Joshi
    PP
    ,  
    Deshmukh
    PK
    ,  
    Salkar
    RG
    .  
    Efficacy of intravenous magnesium sulphate in supraventricular tachyarrhythmias
    J Assoc Physicians India
    1995
    43
    529
    31
    PubMed
    PubMed
  97. Gullestad
    L
    ,  
    Birkeland
    K
    ,  
    Mlstad
    P
    ,  
    Hyer
    MM
    ,  
    Vanberg
    P
    ,  
    Kjekshus
    J
    .  
    The effect of magnesium versus verapamil on supraventricular arrhythmias
    Clin Cardiol
    1993
    16
    429
    34
    PubMed
    CrossRef
    PubMed
  98. James
    MA
    ,  
    Channer
    KS
    ,  
    Papouchado
    M
    ,  
    Rees
    JR
    .  
    Improved control of atrial fibrillation with combined pindolol and digoxin therapy
    Eur Heart J
    1989
    10
    83
    90
    PubMed
    CrossRef
    PubMed
  99. Zehender
    M
    ,  
    Hohnloser
    S
    ,  
    Mller
    B
    ,  
    Meinertz
    T
    ,  
    Just
    H
    .  
    Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up
    J Am Coll Cardiol
    1992
    19
    1054
    9
    PubMed
    CrossRef
    PubMed
  100. Lee
    SH
    ,  
    Chen
    SA
    ,  
    Chiang
    CE
    ,  
    Tai
    CT
    ,  
    Wen
    ZC
    ,  
    Wang
    SP
    ,  
    .  
    Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial
    J Intern Med
    1996
    239
    253
    60
    PubMed
    CrossRef
    PubMed
  101. Botto
    GL
    ,  
    Capucci
    A
    ,  
    Bonini
    W
    ,  
    Boriani
    G
    ,  
    Broffoni
    T
    ,  
    Barone
    P
    ,  
    .  
    Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens
    Int J Cardiol
    1997
    58
    55
    61
    PubMed
    CrossRef
    PubMed
  102. Miller
    MR
    ,  
    McNamara
    RL
    ,  
    Segal
    JB
    ,  
    Kim
    N
    ,  
    Robinson
    KA
    ,  
    Goodman
    SN
    ,  
    .  
    Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials
    J Fam Pract
    2000
    49
    1033
    46
    PubMed
    PubMed
  103. Guo
    GB
    ,  
    Ellenbogen
    KA
    ,  
    Wood
    MA
    ,  
    Stambler
    BS
    .  
    Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability
    J Am Coll Cardiol
    1996
    27
    1083
    9
    PubMed
    CrossRef
    PubMed
  104. Ellenbogen
    KA
    ,  
    Stambler
    BS
    ,  
    Wood
    MA
    ,  
    Sager
    PT
    ,  
    Wesley
    RC
    Jr
    ,  
    Meissner
    MC
    ,  
    .  
    Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study
    J Am Coll Cardiol
    1996
    28
    130
    6
    PubMed
    CrossRef
    PubMed
  105. Stambler
    BS
    ,  
    Wood
    MA
    ,  
    Ellenbogen
    KA
    ,  
    Perry
    KT
    ,  
    Wakefield
    LK
    ,  
    VanderLugt
    JT
    .  
    Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators
    Circulation
    1996
    94
    1613
    21
    PubMed
    CrossRef
    PubMed
  106. Abi-Mansour
    P
    ,  
    Carberry
    PA
    ,  
    McCowan
    RJ
    ,  
    Henthorn
    RW
    ,  
    Dunn
    GH
    ,  
    Perry
    KT
    .  
    Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators
    Am Heart J
    1998
    136
    632
    42
    PubMed
    CrossRef
    PubMed
  107. Suttorp
    MJ
    ,  
    Kingma
    JH
    ,  
    Lie-A-Huen
    L
    ,  
    Mast
    EG
    .  
    Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm
    Am J Cardiol
    1989
    63
    693
    6
    PubMed
    CrossRef
    PubMed
  108. Barranco
    F
    ,  
    Sanchez
    M
    ,  
    Rodriguez
    J
    ,  
    Guerrero
    M
    .  
    Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency
    Intensive Care Med
    1994
    20
    42
    4
    PubMed
    CrossRef
    PubMed
  109. Donovan
    KD
    ,  
    Power
    BM
    ,  
    Hockings
    BE
    ,  
    Dobb
    GJ
    ,  
    Lee
    KY
    .  
    Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation
    Am J Cardiol
    1995
    75
    693
    7
    PubMed
    CrossRef
    PubMed
  110. Capucci
    A
    ,  
    Lenzi
    T
    ,  
    Boriani
    G
    ,  
    Trisolino
    G
    ,  
    Binetti
    N
    ,  
    Cavazza
    M
    ,  
    .  
    Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension
    Am J Cardiol
    1992
    70
    69
    72
    PubMed
    CrossRef
    PubMed
  111. Falk
    RH
    ,  
    Pollak
    A
    ,  
    Singh
    SN
    ,  
    Friedrich
    T
    .  
    Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators
    J Am Coll Cardiol
    1997
    29
    385
    90
    PubMed
    CrossRef
    PubMed
  112. Bianconi
    L
    ,  
    Castro
    A
    ,  
    Dinelli
    M
    ,  
    Alboni
    P
    ,  
    Pappalardo
    A
    ,  
    Richiardi
    E
    ,  
    .  
    Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study
    Eur Heart J
    2000
    21
    1265
    73
    PubMed
    CrossRef
    PubMed
  113. Pedersen
    OD
    ,  
    Bagger
    H
    ,  
    Keller
    N
    ,  
    Marchant
    B
    ,  
    Kber
    L
    ,  
    Torp-Pedersen
    C
    .  
    Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy
    Circulation
    2001
    104
    292
    6
    PubMed
    CrossRef
    PubMed
  114. Lindeboom
    JE
    ,  
    Kingma
    JH
    ,  
    Crijns
    HJ
    ,  
    Dunselman
    PH
    .  
    Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter
    Am J Cardiol
    2000
    85
    1031
    3
    PubMed
    CrossRef
    PubMed
  115. Nrgaard
    BL
    ,  
    Wachtell
    K
    ,  
    Christensen
    PD
    ,  
    Madsen
    B
    ,  
    Johansen
    JB
    ,  
    Christiansen
    EH
    ,  
    .  
    Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group
    Am Heart J
    1999
    137
    1062
    9
    PubMed
    CrossRef
    PubMed
  116. Singh
    S
    ,  
    Zoble
    RG
    ,  
    Yellen
    L
    ,  
    Brodsky
    MA
    ,  
    Feld
    GK
    ,  
    Berk
    M
    ,  
    .  
    Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study
    Circulation
    2000
    102
    2385
    90
    PubMed
    CrossRef
    PubMed
  117. Boriani
    G
    ,  
    Biffi
    M
    ,  
    Capucci
    A
    ,  
    Botto
    GL
    ,  
    Broffoni
    T
    ,  
    Rubino
    I
    ,  
    .  
    Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial
    Ann Intern Med
    1997
    126
    621
    5
    CrossRef
    PubMed
  118. Boriani
    G
    ,  
    Capucci
    A
    ,  
    Lenzi
    T
    ,  
    Sanguinetti
    M
    ,  
    Magnani
    B
    .  
    Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration
    Chest
    1995
    108
    355
    8
    PubMed
    CrossRef
    PubMed
  119. Fresco
    C
    ,  
    Proclemer
    A
    ,  
    Pavan
    A
    ,  
    Buia
    G
    ,  
    Vicentini
    A
    ,  
    Pavan
    D
    ,  
    .  
    Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators
    Clin Cardiol
    1996
    19
    409
    12
    PubMed
    CrossRef
    PubMed
  120. Stroobandt
    R
    ,  
    Stiels
    B
    ,  
    Hoebrechts
    R
    .  
    Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators
    Am J Cardiol
    1997
    79
    418
    23
    PubMed
    CrossRef
    PubMed
  121. Azpitarte
    J
    ,  
    Alvarez
    M
    ,  
    Ban
    O
    ,  
    Garca
    R
    ,  
    Moreno
    E
    ,  
    Martn
    F
    ,  
    .  
    Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study
    Eur Heart J
    1997
    18
    1649
    54
    PubMed
    CrossRef
    PubMed
  122. Bellandi
    F
    ,  
    Dabizzi
    RP
    ,  
    Cantini
    F
    ,  
    Natale
    MD
    ,  
    Niccoli
    L
    .  
    Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillationa single-blind placebo-controlled study
    Cardiovasc Drugs Ther
    1996
    10
    153
    7
    PubMed
    CrossRef
    PubMed
  123. Capucci
    A
    ,  
    Boriani
    G
    ,  
    Rubino
    I
    ,  
    Della Casa
    S
    ,  
    Sanguinetti
    M
    ,  
    Magnani
    B
    .  
    A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm
    Int J Cardiol
    1994
    43
    305
    13
    PubMed
    CrossRef
    PubMed
  124. Weiner
    P
    ,  
    Ganam
    R
    ,  
    Ganem
    R
    ,  
    Zidan
    F
    ,  
    Rabner
    M
    .  
    Clinical course of recent-onset atrial fibrillation treated with oral propafenone
    Chest
    1994
    105
    1013
    6
    PubMed
    CrossRef
    PubMed
  125. Kochiadakis
    GE
    ,  
    Igoumenidis
    NE
    ,  
    Parthenakis
    FI
    ,  
    Chlouverakis
    GI
    ,  
    Vardas
    PE
    .  
    Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study
    J Am Coll Cardiol
    1999
    33
    966
    71
    PubMed
    CrossRef
    PubMed
  126. Bianconi
    L
    ,  
    Mennuni
    M
    .  
    Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial
    Am J Cardiol
    1998
    82
    584
    8
    PubMed
    CrossRef
    PubMed
  127. Ganau
    G
    ,  
    Lenzi
    T
    .  
    Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. FAPS Investigators Study Group
    J Emerg Med
    1998
    16
    383
    7
    PubMed
    CrossRef
    PubMed
  128. Stroobandt
    R
    ,  
    Stiels
    B
    ,  
    Hoebrechts
    R
    .  
    Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators
    Am J Cardiol
    1997
    79
    418
    23
    PubMed
    CrossRef
    PubMed
  129. Baroffio
    R
    ,  
    Tisi
    G
    ,  
    Guzzini
    F
    ,  
    Milvio
    E
    ,  
    Annoni
    P
    .  
    A randomized study comparing digoxin and propafenone in the treatment of recent onset atrial fibrillation
    Clin Drug Invest
    1995
    9
    277
    83
    CrossRef
  130. Kochiadakis
    GE
    ,  
    Igoumenidis
    NE
    ,  
    Simantirakis
    EN
    ,  
    Marketou
    ME
    ,  
    Parthenakis
    FI
    ,  
    Mezilis
    NE
    ,  
    .  
    Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study
    Pacing Clin Electrophysiol
    1998
    21
    2475
    9
    PubMed
    CrossRef
    PubMed
  131. Noc
    M
    ,  
    Stajer
    D
    ,  
    Horvat
    M
    .  
    Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm
    Am J Cardiol
    1990
    65
    679
    80
    PubMed
    CrossRef
    PubMed
  132. Cowan
    JC
    ,  
    Gardiner
    P
    ,  
    Reid
    DS
    ,  
    Newell
    DJ
    ,  
    Campbell
    RW
    .  
    A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction
    J Cardiovasc Pharmacol
    1986
    8
    252
    6
    PubMed
    CrossRef
    PubMed
  133. Hou
    ZY
    ,  
    Chang
    MS
    ,  
    Chen
    CY
    ,  
    Tu
    MS
    ,  
    Lin
    SL
    ,  
    Chiang
    HT
    ,  
    .  
    Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study
    Eur Heart J
    1995
    16
    521
    8
    PubMed
    CrossRef
    PubMed
  134. Deedwania
    PC
    ,  
    Singh
    BN
    ,  
    Ellenbogen
    K
    ,  
    Fisher
    S
    ,  
    Fletcher
    R
    ,  
    Singh
    SN
    .  
    Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators
    Circulation
    1998
    98
    2574
    9
    PubMed
    CrossRef
    PubMed
  135. Joseph
    AP
    ,  
    Ward
    MR
    .  
    A prospective, randomized, controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation
    Ann Emerg Med
    2000
    36
    1
    9
    PubMed
    CrossRef
    PubMed
  136. Kochiadakis
    GE
    ,  
    Igoumenidis
    NE
    ,  
    Marketou
    ME
    ,  
    Solomou
    MC
    ,  
    Kanoupakis
    EM
    ,  
    Vardas
    PE
    .  
    Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
    Am J Cardiol
    1998
    81
    995
    8
    PubMed
    CrossRef
    PubMed
  137. Vardas
    PE
    ,  
    Kochiadakis
    GE
    ,  
    Igoumenidis
    NE
    ,  
    Tsatsakis
    AM
    ,  
    Simantirakis
    EN
    ,  
    Chlouverakis
    GI
    .  
    Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study
    Chest
    2000
    117
    1538
    45
    PubMed
    CrossRef
    PubMed
  138. Peuhkurinen
    K
    ,  
    Niemel
    M
    ,  
    Ylitalo
    A
    ,  
    Linnaluoto
    M
    ,  
    Lilja
    M
    ,  
    Juvonen
    J
    .  
    Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation
    Am J Cardiol
    2000
    85
    462
    5
    PubMed
    CrossRef
    PubMed
  139. Galve
    E
    ,  
    Rius
    T
    ,  
    Ballester
    R
    ,  
    Artaza
    MA
    ,  
    Arnau
    JM
    ,  
    Garca-Dorado
    D
    ,  
    .  
    Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study
    J Am Coll Cardiol
    1996
    27
    1079
    82
    PubMed
    CrossRef
    PubMed
  140. Cotter
    G
    ,  
    Blatt
    A
    ,  
    Kaluski
    E
    ,  
    Metzkor-Cotter
    E
    ,  
    Koren
    M
    ,  
    Litinski
    I
    ,  
    .  
    Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study
    Eur Heart J
    1999
    20
    1833
    42
    PubMed
    CrossRef
    PubMed
  141. Galpern
    J
    ,  
    Elizari
    MV
    ,  
    Chiale
    PA
    ,  
    Molina
    RT
    ,  
    Ledesma
    R
    ,  
    Scapn
    AO
    ,  
    .  
    Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial
    J Cardiovasc Pharmacol Ther
    2001
    6
    341
    50
    PubMed
    CrossRef
    PubMed
  142. Singh
    S
    ,  
    Saini
    RK
    ,  
    DiMarco
    J
    ,  
    Kluger
    J
    ,  
    Gold
    R
    ,  
    Chen
    YW
    .  
    Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group
    Am J Cardiol
    1991
    68
    1227
    30
    PubMed
    CrossRef
    PubMed
  143. Sung
    RJ
    ,  
    Tan
    HL
    ,  
    Karagounis
    L
    ,  
    Hanyok
    JJ
    ,  
    Falk
    R
    ,  
    Platia
    E
    ,  
    .  
    Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group
    Am Heart J
    1995
    129
    739
    48
    PubMed
    CrossRef
    PubMed
  144. Baldi
    N
    ,  
    Russo
    VA
    ,  
    Lenti
    V
    ,  
    Marasco
    G
    ,  
    Polimeni
    G
    ,  
    Conserva
    R
    ,  
    .  
    Relation between plasma levels and efficacy of flecainide and propafenone for treatment of atrial fibrillation of recent onset
    New Trends Arrhythmias
    1993
    9
    899
    906
  145. Martnez-Marcos
    FJ
    ,  
    Garca-Garmendia
    JL
    ,  
    Ortega-Carpio
    A
    ,  
    Fernndez-Gmez
    JM
    ,  
    Santos
    JM
    ,  
    Camacho
    C
    .  
    Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
    Am J Cardiol
    2000
    86
    950
    3
    PubMed
    CrossRef
    PubMed
  146. Reisinger
    J
    ,  
    Gatterer
    E
    ,  
    Heinze
    G
    ,  
    Wiesinger
    K
    ,  
    Zeindlhofer
    E
    ,  
    Gattermeier
    M
    ,  
    .  
    Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation
    Am J Cardiol
    1998
    81
    1450
    4
    PubMed
    CrossRef
    PubMed
  147. Madrid
    AH
    ,  
    Moro
    C
    ,  
    Marn-Huerta
    E
    ,  
    Mestre
    JL
    ,  
    Novo
    L
    ,  
    Costa
    A
    .  
    Comparison of flecainide and procainamide in cardioversion of atrial fibrillation
    Eur Heart J
    1993
    14
    1127
    31
    PubMed
    CrossRef
    PubMed
  148. Vos
    MA
    ,  
    Golitsyn
    SR
    ,  
    Stangl
    K
    ,  
    Ruda
    MY
    ,  
    Van Wijk
    LV
    ,  
    Harry
    JD
    ,  
    .  
    Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group
    Heart
    1998
    79
    568
    75
    PubMed
    CrossRef
    PubMed
  149. Volgman
    AS
    ,  
    Carberry
    PA
    ,  
    Stambler
    B
    ,  
    Lewis
    WR
    ,  
    Dunn
    GH
    ,  
    Perry
    KT
    ,  
    .  
    Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
    J Am Coll Cardiol
    1998
    31
    1414
    9
    PubMed
    CrossRef
    PubMed
  150. Bertini
    G
    ,  
    Conti
    A
    ,  
    Fradella
    G
    ,  
    Francardelli
    L
    ,  
    Giglioli
    C
    ,  
    Mangialavori
    G
    ,  
    .  
    Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias
    J Emerg Med
    1990
    8
    15
    20
    PubMed
    CrossRef
    PubMed
  151. Hohnloser
    SH
    ,  
    van de Loo
    A
    ,  
    Baedeker
    F
    .  
    Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine
    J Am Coll Cardiol
    1995
    26
    852
    8
    PubMed
    CrossRef
    PubMed
  152. Halinen
    MO
    ,  
    Huttunen
    M
    ,  
    Paakkinen
    S
    ,  
    Tarssanen
    L
    .  
    Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial)
    Am J Cardiol
    1995
    76
    495
    8
    PubMed
    CrossRef
    PubMed
  153. Roden
    DM
    .  
    Risks and benefits of antiarrhythmic therapy
    N Engl J Med
    1994
    331
    785
    91
    PubMed
    CrossRef
    PubMed
  154. Falk
    RH
    .  
    Proarrhythmia in patients treated for atrial fibrillation or flutter
    Ann Intern Med
    1992
    117
    141
    50
    CrossRef
    PubMed
  155. Maisel
    WH
    ,  
    Kuntz
    KM
    ,  
    Reimold
    SC
    ,  
    Lee
    TH
    ,  
    Antman
    EM
    ,  
    Friedman
    PL
    ,  
    .  
    Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
    Ann Intern Med
    1997
    127
    281
    4
    CrossRef
    PubMed
  156. Prystowsky
    EN
    .  
    Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia
    Clin Cardiol
    1994
    17
    II7
    10
    PubMed
    PubMed
  157. Zimetbaum
    PJ
    ,  
    Schreckengost
    VE
    ,  
    Cohen
    DJ
    ,  
    Lemery
    R
    ,  
    Love
    D
    ,  
    Epstein
    LM
    ,  
    .  
    Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation
    Am J Cardiol
    1999
    83
    450
    2
    PubMed
    CrossRef
    PubMed
  158. Blanc
    JJ
    ,  
    Voinov
    C
    ,  
    Maarek
    M
    .  
    Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group
    Am J Cardiol
    1999
    84
    1029
    32
    PubMed
    CrossRef
    PubMed
  159. Alp
    NJ
    ,  
    Bell
    JA
    ,  
    Shahi
    M
    .  
    Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation
    Heart
    2000
    84
    37
    40
    PubMed
    CrossRef
    PubMed
  160. Levi
    G
    ,  
    Proto
    C
    ,  
    Rovetta
    A
    .  
    Double-blind evaluation of practolol and quinidine in the treatment of chronic atrial fibrillation
    Cardiology
    1973
    58
    364
    8
    PubMed
    CrossRef
    PubMed
  161. Innes
    GD
    ,  
    Vertesi
    L
    ,  
    Dillon
    EC
    ,  
    Metcalfe
    C
    .  
    Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation
    Ann Emerg Med
    1997
    29
    126
    34
    PubMed
    CrossRef
    PubMed
  162. Lown
    B
    ,  
    Perlroth
    MG
    ,  
    Kaidbey
    S
    ,  
    Abe
    T
    ,  
    Harken
    DE
    .  
    Cardioversion of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients
    N Engl J Med
    1963
    269
    325
    31
    PubMed
    CrossRef
    PubMed
  163. Scott
    ME
    ,  
    Geddes
    JS
    ,  
    Patterson
    GC
    .  
    The long term prognosis of atrial fibrillation following direct current conversion
    Ulster Med J
    1968
    37
    155
    61
    PubMed
    PubMed
  164. McCarthy
    C
    ,  
    Varghese
    PJ
    ,  
    Barritt
    DW
    .  
    Prognosis of atrial arrhythmias treated by electrical counter shock therapy. A three-year follow-up
    Br Heart J
    1969
    31
    496
    500
    PubMed
    CrossRef
    PubMed
  165. Gunning
    JF
    ,  
    Kristinsson
    A
    ,  
    Miller
    G
    ,  
    Saunders
    K
    .  
    Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine
    Br Heart J
    1970
    32
    462
    6
    PubMed
    CrossRef
    PubMed
  166. Bjerkelund
    CJ
    ,  
    Orning
    OM
    .  
    The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation
    Am J Cardiol
    1969
    23
    208
    16
    PubMed
    CrossRef
    PubMed
  167. Klein
    AL
    ,  
    Grimm
    RA
    ,  
    Murray
    RD
    ,  
    Apperson-Hansen
    C
    ,  
    Asinger
    RW
    ,  
    Black
    IW
    ,  
    .  
    Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
    N Engl J Med
    2001
    344
    1411
    20
    PubMed
    CrossRef
    PubMed
  168. Page
    RL
    ,  
    Kerber
    RE
    ,  
    Russell
    JK
    ,  
    Trouton
    T
    ,  
    Waktare
    J
    ,  
    Gallik
    D
    ,  
    .  
    Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial
    J Am Coll Cardiol
    2002
    39
    1956
    63
    PubMed
    CrossRef
    PubMed
  169. Lvy
    S
    ,  
    Lauribe
    P
    ,  
    Dolla
    E
    ,  
    Kou
    W
    ,  
    Kadish
    A
    ,  
    Calkins
    H
    ,  
    .  
    A randomized comparison of external and internal cardioversion of chronic atrial fibrillation
    Circulation
    1992
    86
    1415
    20
    PubMed
    CrossRef
    PubMed
  170. Alt
    E
    ,  
    Ammer
    R
    ,  
    Schmitt
    C
    ,  
    Evans
    F
    ,  
    Lehmann
    G
    ,  
    Pasquantonio
    J
    ,  
    .  
    A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion
    Eur Heart J
    1997
    18
    1796
    804
    PubMed
    CrossRef
    PubMed
  171. Mittal
    S
    ,  
    Ayati
    S
    ,  
    Stein
    KM
    ,  
    Schwartzman
    D
    ,  
    Cavlovich
    D
    ,  
    Tchou
    PJ
    ,  
    .  
    Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks
    Circulation
    2000
    101
    1282
    7
    PubMed
    CrossRef
    PubMed
  172. Niebauer
    MJ
    ,  
    Chunk
    MK
    ,  
    Wilkoff
    BL
    ,  
    Schweikert
    RA
    ,  
    Saliba
    WI
    ,  
    Jaeger
    FJ
    ,  
    .  
    Success rate of the rectilinear biphasic waveform in atrial cardioversion in a large cohort of patients [Abstract]
    Circulation
    2000
    102
    II574f
  173. Rasmussen
    K
    ,  
    Wang
    H
    ,  
    Fausa
    D
    .  
    Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial
    Acta Med Scand Suppl
    1981
    645
    23
    8
    PubMed
    PubMed
  174. Byrne-Quinn
    E
    ,  
    Wing
    AJ
    .  
    Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate
    Br Heart J
    1970
    32
    370
    6
    PubMed
    CrossRef
    PubMed
  175. Hillestad
    L
    ,  
    Bjerkelund
    C
    ,  
    Dale
    J
    ,  
    Maltau
    J
    ,  
    Storstein
    O
    .  
    Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study
    Br Heart J
    1971
    33
    518
    21
    PubMed
    CrossRef
    PubMed
  176. Bianconi
    L
    ,  
    Mennuni
    M
    ,  
    Lukic
    V
    ,  
    Castro
    A
    ,  
    Chieffi
    M
    ,  
    Santini
    M
    .  
    Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study
    J Am Coll Cardiol
    1996
    28
    700
    6
    PubMed
    CrossRef
    PubMed
  177. Bianconi
    L
    ,  
    Mennuni
    M
    ,  
    Lukic
    V
    ,  
    Tassoni
    G
    ,  
    Santini
    M
    .  
    Pretreatment with oral propafenone in electrical cardioversion of chronic atrial fibrillation
    New Trends Arrhythmias
    1993
    9
    1017
    20
  178. Oral
    H
    ,  
    Souza
    JJ
    ,  
    Michaud
    GF
    ,  
    Knight
    BP
    ,  
    Goyal
    R
    ,  
    Strickberger
    SA
    ,  
    .  
    Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
    N Engl J Med
    1999
    340
    1849
    54
    PubMed
    CrossRef
    PubMed
  179. Moreyra
    E
    ,  
    Finkelhor
    RS
    ,  
    Cebul
    RD
    .  
    Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials
    Am Heart J
    1995
    129
    71
    5
    PubMed
    CrossRef
    PubMed
  180. Klein
    AL
    ,  
    Murray
    RD
    ,  
    Grimm
    RA
    .  
    Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation
    J Am Coll Cardiol
    2001
    37
    691
    704
    PubMed
    CrossRef
    PubMed
  181. Goldman
    MJ
    .  
    The management of chronic atrial fibrillation: indications for and method of conversion to normal rhythm
    Progress in Cardiovascular Diseases
    1960
    2
    465
    79
    CrossRef
  182. Leung
    DY
    ,  
    Davidson
    PM
    ,  
    Cranney
    GB
    ,  
    Walsh
    WF
    .  
    Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram
    Am J Cardiol
    1997
    79
    626
    9
    PubMed
    CrossRef
    PubMed
  183. Stllberger
    C
    ,  
    Chnupa
    P
    ,  
    Kronik
    G
    ,  
    Brainin
    M
    ,  
    Finsterer
    J
    ,  
    Schneider
    B
    ,  
    .  
    Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi
    Ann Intern Med
    1998
    128
    630
    8
    CrossRef
    PubMed
  184. Fatkin
    D
    ,  
    Kuchar
    DL
    ,  
    Thorburn
    CW
    ,  
    Feneley
    MP
    .  
    Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for atrial stunning as a mechanism of thromboembolic complications
    J Am Coll Cardiol
    1994
    23
    307
    16
    PubMed
    CrossRef
    PubMed
  185. Stoddard
    MF
    ,  
    Dawkins
    PR
    ,  
    Prince
    CR
    ,  
    Longaker
    RA
    .  
    Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation
    Am Heart J
    1995
    129
    1204
    15
    PubMed
    CrossRef
    PubMed
  186. Harjai
    K
    ,  
    Mobarek
    S
    ,  
    Abi-Samra
    F
    ,  
    Gilliland
    Y
    ,  
    Davison
    N
    ,  
    Drake
    K
    ,  
    .  
    Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion
    Am J Cardiol
    1998
    81
    1125
    9
    PubMed
    CrossRef
    PubMed
  187. Hirsh
    J
    ,  
    Dalen
    J
    ,  
    Guyatt
    G
    .  
    The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians
    Chest
    2001
    119
    1S
    2S
    PubMed
    CrossRef
    PubMed
  188. Hwang
    JJ
    ,  
    Chen
    JJ
    ,  
    Lin
    SC
    ,  
    Tseng
    YZ
    ,  
    Kuan
    P
    ,  
    Lien
    WP
    ,  
    .  
    Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations
    Am J Cardiol
    1993
    72
    677
    81
    PubMed
    CrossRef
    PubMed
  189. Manning
    WJ
    ,  
    Weintraub
    RM
    ,  
    Waksmonski
    CA
    ,  
    Haering
    JM
    ,  
    Rooney
    PS
    ,  
    Maslow
    AD
    ,  
    .  
    Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study
    Ann Intern Med
    1995
    123
    817
    22
    CrossRef
    PubMed
  190. Fatkin
    D
    ,  
    Scalia
    G
    ,  
    Jacobs
    N
    ,  
    Burstow
    D
    ,  
    Leung
    D
    ,  
    Walsh
    W
    ,  
    .  
    Accuracy of biplane transesophageal echocardiography in detecting left atrial thrombus
    Am J Cardiol
    1996
    77
    321
    3
    PubMed
    CrossRef
    PubMed
  191. Manning
    WJ
    ,  
    Silverman
    DI
    ,  
    Gordon
    SP
    ,  
    Krumholz
    HM
    ,  
    Douglas
    PS
    .  
    Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi
    N Engl J Med
    1993
    328
    750
    5
    PubMed
    CrossRef
    PubMed
  192. Seidl
    K
    ,  
    Rameken
    M
    ,  
    Drgemller
    A
    ,  
    Vater
    M
    ,  
    Brandt
    A
    ,  
    Schwacke
    H
    ,  
    .  
    Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study
    J Am Coll Cardiol
    2002
    39
    1436
    42
    PubMed
    CrossRef
    PubMed
  193. Seto
    TB
    ,  
    Taira
    DA
    ,  
    Tsevat
    J
    ,  
    Manning
    WJ
    .  
    Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation
    J Am Coll Cardiol
    1997
    29
    122
    30
    PubMed
    CrossRef
    PubMed
  194. Bellandi
    F
    ,  
    Cantini
    F
    ,  
    Pedone
    T
    ,  
    Palchetti
    R
    ,  
    Bamoshmoosh
    M
    ,  
    Dabizzi
    RP
    .  
    Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study
    Clin Cardiol
    1995
    18
    631
    4
    PubMed
    CrossRef
    PubMed
  195. Tommaso
    C
    ,  
    McDonough
    T
    ,  
    Parker
    M
    ,  
    Talano
    JV
    .  
    Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil
    Arch Intern Med
    1983
    143
    877
    81
    PubMed
    CrossRef
    PubMed
  196. Roy
    D
    ,  
    Talajic
    M
    ,  
    Dorian
    P
    ,  
    Connolly
    S
    ,  
    Eisenberg
    MJ
    ,  
    Green
    M
    ,  
    .  
    Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators
    N Engl J Med
    2000
    342
    913
    20
    PubMed
    CrossRef
    PubMed
  197. Kochiadakis
    GE
    ,  
    Marketou
    ME
    ,  
    Igoumenidis
    NE
    ,  
    Chrysostomakis
    SI
    ,  
    Mavrakis
    HE
    ,  
    Kaleboubas
    MD
    ,  
    .  
    Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
    Pacing Clin Electrophysiol
    2000
    23
    1883
    7
    PubMed
    CrossRef
    PubMed
  198. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med
    1989
    321
    406
    12
    PubMed
    CrossRef
    PubMed
  199. Coplen
    SE
    ,  
    Antman
    EM
    ,  
    Berlin
    JA
    ,  
    Hewitt
    P
    ,  
    Chalmers
    TC
    .  
    Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
    Circulation
    1990
    82
    1106
    16
    PubMed
    CrossRef
    PubMed
  200. Naccarelli
    GV
    ,  
    Dorian
    P
    ,  
    Hohnloser
    SH
    ,  
    Coumel
    P
    .  
    Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group
    Am J Cardiol
    1996
    77
    53A
    59A
    PubMed
    CrossRef
    PubMed
  201. van Wijk
    LM
    ,  
    den Heijer
    P
    ,  
    Crijns
    HJ
    ,  
    van Gilst
    WH
    ,  
    Lie
    KI
    .  
    Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation
    J Cardiovasc Pharmacol
    1989
    13
    32
    6
    PubMed
    CrossRef
    PubMed
  202. Aliot
    E
    ,  
    Denjoy
    I
    .  
    Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group
    Am J Cardiol
    1996
    77
    66A
    71A
    PubMed
    CrossRef
    PubMed
  203. Van Gelder
    IC
    ,  
    Crijns
    HJ
    ,  
    Van Gilst
    WH
    ,  
    Van Wijk
    LM
    ,  
    Hamer
    HP
    ,  
    Lie
    KI
    .  
    Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter
    Am J Cardiol
    1989
    64
    1317
    21
    PubMed
    CrossRef
    PubMed
  204. Crijns
    HJ
    ,  
    Gosselink
    AT
    ,  
    Lie
    KI
    .  
    Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group
    Cardiovasc Drugs Ther
    1996
    10
    145
    52
    PubMed
    CrossRef
    PubMed
  205. Lee
    SH
    ,  
    Chen
    SA
    ,  
    Tai
    CT
    ,  
    Chiang
    CE
    ,  
    Wen
    ZC
    ,  
    Chen
    YJ
    ,  
    .  
    Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation
    Am J Cardiol
    1997
    79
    905
    8
    PubMed
    CrossRef
    PubMed
  206. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group
    Circulation
    1995
    92
    2550
    7
    PubMed
    PubMed
  207. Reimold
    SC
    ,  
    Cantillon
    CO
    ,  
    Friedman
    PL
    ,  
    Antman
    EM
    .  
    Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
    Am J Cardiol
    1993
    71
    558
    63
    PubMed
    CrossRef
    PubMed
  208. Bellandi
    F
    ,  
    Simonetti
    I
    ,  
    Leoncini
    M
    ,  
    Frascarelli
    F
    ,  
    Giovannini
    T
    ,  
    Maioli
    M
    ,  
    .  
    Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation
    Am J Cardiol
    2001
    88
    640
    5
    PubMed
    CrossRef
    PubMed
  209. de Paola
    AA
    ,  
    Veloso
    HH
    .  
    Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of So Paulo
    Am J Cardiol
    1999
    84
    1033
    7
    PubMed
    CrossRef
    PubMed
  210. Benditt
    DG
    ,  
    Williams
    JH
    ,  
    Jin
    J
    ,  
    Deering
    TF
    ,  
    Zucker
    R
    ,  
    Browne
    K
    ,  
    .  
    Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group
    Am J Cardiol
    1999
    84
    270
    7
    PubMed
    CrossRef
    PubMed
  211. Juul-Mller
    S
    ,  
    Edvardsson
    N
    ,  
    Rehnqvist-Ahlberg
    N
    .  
    Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation
    Circulation
    1990
    82
    1932
    9
    PubMed
    CrossRef
    PubMed
  212. Pritchett
    EL
    ,  
    Page
    RL
    ,  
    Connolly
    SJ
    ,  
    Marcello
    SR
    ,  
    Schnell
    DJ
    ,  
    Wilkinson
    WE
    .  
    Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators
    J Am Coll Cardiol
    2000
    36
    794
    802
    PubMed
    CrossRef
    PubMed
  213. Sdermark
    T
    ,  
    Jonsson
    B
    ,  
    Olsson
    A
    ,  
    Or
    L
    ,  
    Wallin
    H
    ,  
    Edhag
    O
    ,  
    .  
    Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm
    Br Heart J
    1975
    37
    486
    92
    PubMed
    CrossRef
    PubMed
  214. Bellandi
    F
    ,  
    Dabizzi
    RP
    ,  
    Niccoli
    L
    ,  
    Cantini
    F
    .  
    Propafenone and sotalol in the prevention of paroxysmal atrial fibrillation: long-term safety and efficacy study
    Current Therapeutic Research
    1995
    56
    1154
    68
    CrossRef
  215. Antonielli
    E
    ,  
    Pizzuti
    A
    ,  
    Plinks
    A
    ,  
    Tanga
    M
    ,  
    Gruber
    N
    ,  
    Michelassi
    C
    ,  
    .  
    Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation
    J Am Coll Cardiol
    2002
    39
    1443
    9
    PubMed
    CrossRef
    PubMed
Figure 1.

Absolute rates of stroke and hemorrhage for trials comparing warfarin or aspirin with control.

Figure 2.

Proportions of patients who had successful pharmacologic intervention.

Figure 3.

Proportions of patients who had successful maintenance of sinus rhythm.

Table 1. Meta-Analysis of Primary Prevention of Stroke in Atrial Fibrillation

Table 1. Meta-Analysis of Primary Prevention of Stroke in Atrial Fibrillation

Table 2. Pooled Results for the Efficacy and Adverse Effects of Drugs Used in Acute Conversion of Atrial Fibrillation

Table 2. Pooled Results for the Efficacy and Adverse Effects of Drugs Used in Acute Conversion of Atrial Fibrillation

Table 3. Pooled Results of Randomized, Controlled Trials of Drugs for Maintenance of Sinus Rhythm after Conversion of Atrial Fibrillation

Table 3. Pooled Results of Randomized, Controlled Trials of Drugs for Maintenance of Sinus Rhythm after Conversion of Atrial Fibrillation

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Management of Newly Detected Atrial Fibrillation: Recommendations from the American College of Physicians and the American Academy of Family Physicians

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. Ann Intern Med. ;139:1018–1033. doi: 10.7326/0003-4819-139-12-200312160-00012

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2003;139(12):1018-1033.

DOI: 10.7326/0003-4819-139-12-200312160-00012

©
2003 American College of Physicians
134 Citations

See Also

Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians
Management of Newly Detected Atrial Fibrillation: Recommendations from the American College of Physicians and the American Academy of Family Physicians
View MoreView Less

Related Articles

Rate- and Rhythm-Control Therapies in Patients With Atrial Fibrillation: A Systematic Review
Annals of Internal Medicine; 160 (11): 760-773
Ablation reduced recurrent atrial tachyarrhythmia more than antiarrhythmic drugs in paroxysmal AF
Annals of Internal Medicine; 160 (10): JC5
Short-term was less effective than long-term flecainide for preventing recurrent AF after cardioversion
Annals of Internal Medicine; 157 (6): JC3-9
Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation?
Annals of Internal Medicine; 141 (9): 720-726
View MoreView Less

Journal Club

Ablation reduced recurrent atrial tachyarrhythmia more than antiarrhythmic drugs in paroxysmal AF
Annals of Internal Medicine; 160 (10): JC5
Short-term was less effective than long-term flecainide for preventing recurrent AF after cardioversion
Annals of Internal Medicine; 157 (6): JC3-9
Review: In noncardiac surgery, amiodarone, β-blocker, or statin prophylaxis reduces postoperative AF
Annals of Internal Medicine; 169 (2): JC7
Review: After PCI in AF, OAC plus single vs dual antiplatelets reduces major bleeding; no difference for MACE
Annals of Internal Medicine; 169 (2): JC8
View MoreView Less

Related Point of Care

Atrial Fibrillation
Annals of Internal Medicine; 166 (5): ITC33-ITC48
Atrial Fibrillation
Annals of Internal Medicine; 153 (11): ITC6-1
Atrial Fibrillation
Annals of Internal Medicine; 149 (9): ITC5-1
Smoking Cessation
Annals of Internal Medicine; 164 (5): ITC33-ITC48
View MoreView Less

Related Topics

Cardiology
Guidelines
Rhythm Disorders and Devices

Cardiology, Guidelines, Rhythm Disorders and Devices.

PubMed Articles

Suicide attempt in patients with atrial fibrillation - A nationwide cohort study.
Prog Neuropsychopharmacol Biol Psychiatry 2019.
[Cardiomyopathy in a 22-year-old man with a long history of methamphetamine abuse].
Internist (Berl) 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×